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ABSTRACT 
The targeting of exogenous antigen into the MHC class 1-restricted presentation 
pathway is required for the induction of cytotoxic T lymphocytes (CTL) which have 
been shown to be an important component of the protective response to intracellular 
antigens and also induce immunity to tumour cells. Thus, induction of a CTL 
response is an important goal in vaccine research and a number of delivery systems 
are being investigated. 
Certain cytotoxic proteins that catalytically modify substrates in the cytosol of 
mammalian cells undergo retrograde vesicular transport from the cell surface to the 
endoplasmic reticulum before translocating into the cytosol. In this study, Shiga-like 
toxin 1 (SLT) from Escherichia coil 0157: H7 was used to deliver an antigenic 
peptide for presentation by major histocompatibility complex (MHC) class I 
molecules. The SLT A chain was genetically fused with a nonamer peptide derived 
from influenza virus Matrix protein, positioned at either the N- or C-terminus of the 
toxin (designated SLT N-Ma or C-Ma). The SLT coding sequence was also mutated 
to convert an active site glutamate into aspartate to significantly reduce ribosome- 
inactivating activity, and hence the inherent cytotoxicity of the toxin chimeras. 
Recombinant holotoxins carrying the viral peptide were expressed in E. coil and 
purified to homogeneity before use. HLA-A2-transfected HeLa cells were allowed 
to internalize the disarmed toxin-peptide chimeras and were used as targets of 
influenza Matrix-specific cytotoxic T lymphocytes (CTL). HLA-A2-matched cells, 
unable to internalize SLT, were used as negative controls. 
Results from this study show that SLT N-Ma but not SLT C-Ma is capable of 
sensitizing HeLa A2 cells for lysis by cytotoxic T -lymphocytes (CTL) whilst no 
killing of SLT-resistant cells has been observed. Treatment of cells with the Golgi 
stack-disrupting agent brefeldin A successfully blocked the presentation of the M58- 
66 epitope at the cell surface, confirming that the antigenic peptide was liberated 
intracellularly. 
This strategy was repeated for ricin A-chain, placing a nonamer peptide derived from 
influenza virus nucleoprotein at either the N-terminus or within an external loop of 
the toxin A-chain (designated RTA N-NP or Clal-NP). Fusion proteins were 
expressed in E. coli and purified, followed by reassociation with ricin B-chain. 
Preliminary results have failed to show the delivery of peptide antigen to class-i 
molecules by the ricin chimeras. This work is ongoing. 
This thesis demonstrates that Shiga-like toxin-1, known to be endocytosed from the 
cell surface to the ER lumen and then transferred to the cytosol of eukaryotic cells, 
can intersect the MHC class 1 presentation pathway and effectively carry antigenic 
peptide to class 1 molecules in vitro. This approach opens up new possibilities for 
the generation of CD8+ T-cell vaccines for use against infectious agents, cancer and 
autoimmune disorders. 
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CHAPTER I 
INTRODUCTION 
Chapter 1 
Introduction 
1.1 General Overview 
The basis for the immune response against virally infected or transformed cells is the 
recognition by cytotoxic T lymphocytes (CTL) of antigenic peptides. These are 
derived from cytosolic proteins and presented on the cell surface by major 
histocompatibility complex (MHC) class 1 molecules. The main steps in this 
process are the degradation of both self and foreign proteins to short peptides mainly 
by proteasomes located in the cytosol, translocation of peptides into the lumen of the 
endoplasmic reticulum (ER) and their assembly with MHC class 1 molecules. 
Following secretion as a MHC-peptide complex to the cell surface, the complex is 
recognised as presenting self or foreign peptides and an appropriate immune 
response made, ultimately leading to the death of virally infected or tumour cells 
(Cerundolo and Braud, 1996). 
Thus, as a general rule, MHC class-I molecules present endogenously derived 
peptide epitopes from cytosolic and nuclear proteins to CD8+ T lymphocytes (CTL) 
whereas peptides derived from exogenous, e. g. bacterial proteins are generated in the 
endocytic pathway and presented by MHC class II molecules to CD4+ T helper (Th) 
lymphocytes (Pieters, 1997). The two T cell responses lead to an effect that is 
appropriate to the type of infection. Induction of CD4+ T helper cells stimulates 
their production of cytokines, one effect of which is to activate B-cells to produce 
antibodies. This response is effective in the clearance of extracellular pathogens. In 
1 
contrast activated CTL secrete proteolytic enzymes resulting in the direct lysis of 
bound antigen presenting cells. This action prevents or at least controls an 
intracellular pathogenic infection by removing infected cells. 
Since CTL are an important component of the protective and therapeutic immune 
response to viral infections and tumours (Zinkernagel et al., 1996, Meir et al., 1995, 
Romero et al., 1998) different vaccine strategies are being developed that allow the 
presentation of soluble exogenous antigens by MHC class 1 molecules and 
stimulation of CTL. Whereas direct immunisation with a viral protein tends to lead 
to antigen endocytosis and a subsequent MHC class II response, delivery of 
exogenous antigens into the cytosol and their introduction into the MHC class 1 
pathway may lead to the generation of protective CTL. 
Previous studies have used toxins such as diphtheria (DT), anthrax and 
Pseudomonas exotoxin A (PE) to deliver peptide epitopes into the MHC class 1 
pathway (Donelly et al., 1993, Goletz et al., 1997, Ballard et al., 1996,1998). With 
one exception (Goletz et al., 1997), the intracelluar routing pathway or the location 
of processing of the toxin fusion proteins was not known or investigated. 
In this study ribosome inactivating proteins (RIPs), namely Shiga-like toxin 1 (SLT) 
and ricin have been tested for their ability to deliver viral peptides into the MHC 
class 1 processing pathway. The intracellular uptake pathway taken by SLT and 
ricin, which involves transport from the cell surface to the endoplasmic reticulum 
(ER), has been well defined. Based on this knowledge the routing of the toxin 
2 
chimera and its processing, either directly in the ER lumen or after translocation of 
the toxin-A chain, has been investigated. 
This introduction will first describe ribosome inactivating proteins with relation to 
how they may parisitise intracellular transport pathways in order to intoxicate cells. 
The current knowledge of the MHC class 1 pathway will then be discussed. Finally, 
various vaccine approaches will be reviewed and their potential against certain viral 
pathogens and tumour cells discussed. 
1.2 Protein toxins produced by plants and bacteria 
1.2.1 Functionally analogous A-B toxins 
Some plants and bacteria produce proteins that are potently toxic to mammalian 
cells. These toxins all act by catalytically modifying essential cellular components, 
many leading to the inhibition of protein synthesis. To reach their targets, these 
toxins must bind and gain entry into cells. To achieve this they exist as a family of 
bipartite A-B toxins consisting of a catalytically active polypeptide A-chain 
associated with one or more cell-binding subunits (B-chain) (Figure 1.1). 
These toxins bind to receptors on the surface of susceptible cells and enter by 
endocytosis in a clathrin-dependent or independent manner, depending on the chosen 
receptor. The toxins must then translocate across an intracellular membrane in order 
to reach their cytosolic target substrates. Translocation can be achieved from 
acidified 
3 
Shiga toxin / Shiga-like toxin-I 
S-S [Fiý 
SLT A2 B 
11 
ricin 
S-S 
RTA B 
cholera toxin 
S-S 
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diphtheria toxin 
S-S 
DT 0 
Pseudomonas exotoxin A 
S-S 
u P PE A 
Figure 1.1 Schematic representation of a selection of A-B plant and bacterial toxins 
Cell binding domains are labelled in blue and known translocation domains in green. 
Catalytic domains are labelled in grey. Disulfide bonds that covalently link a trypsin- 
sensitive site or two fragments are labelled. Shigal Shiga-like toxin and ricin represent 
members of ribosome inactivating proteins (RIPs) by their RNA N-glycosidase activity. 
Cholera, diphtheria and Pseudomonas exotoxin A are members of a toxin family that 
function in the ADP-ribosylation of target molecules. 
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endosomes, as demonstrated by diphtheria toxin. Others are transported beyond 
endosomes in a retrograde manner via the trans Golgi network (TGN) to the ER from 
which it has been shown translocation occurs (Sandvig et al, 1992). These toxins 
include Shiga toxin, the E. coli produced Shiga-like toxins, E. coli heat-labile 
enterotoxin, cholera toxin, pertussis toxin, Pseudomonas exotoxin A and ricin. 
Protein toxins can be further grouped by their precise mode of action. DT and PE 
catalytically inhibit protein synthesis by irreversibly modifying elongation factor-2 
by ADP ribosylation of a critical modified histidine (termed diphtamide). SLT and 
ricin, the toxins in this study, belong to a group of toxins known as ribosome 
inactivating proteins (RIPs), which again interfere with the ability of elongation 
factors to interact with ribosomes. These enzymes are RNA specific N-glycosidases 
and their target lies within the 60 S subunits of 80 S ribosomes. Removal of a 
specific adenine residue renders the ribosomes unable to bind elongation factor-2, 
thus blocking elongation cycles of protein synthesis (Lord and Roberts, 1991). 
1.2.2 Structures and modes of action of ribosome inactivating proteins 
Many plant tissues produce single chain proteins that can enzymatically remove a 
specific adenine residue from ribosomal RNA. Classified by their structure, they are 
termed type I RIPs, consisting of a single catalytic polypeptide, around 30kDa in size 
and include toxins such as pokeweed antiviral protein (PAP). Type II RIPs are 
defined as consisting of a catalytic polypeptide (A-chain) joined by a disulfide bond 
to a cell-binding polypeptide chain (B-chain) which in the case of all plant RIPs, 
such as ricin, is a galactose-binding lectin whose molecular weight is also around 
5 
30kDa. The A-chain of these type II plant RIPs is structurally and functionally 
homologous to the single chain RIPs. The bacterial toxins, Shigella toxin and the 
related Shiga-like toxins from certain strains of E. coli also fall into this category of 
type II RIPs although their structure is different from other A-B toxins described, 
with the catalytic A-chain interacting non covalently with a pentamer of B-chains 
(AB5)" 
1.2.3 Structure of Shiga-like toxin-i 
Shiga-like toxin-1 (SLT) from E. coli 0157: H7 is a Shiga toxin (ST) analogue 
comprising an enzymatic A chain (32,225 kDa) non-covalently associated with a 
pentamer of B subunits (7,691 kDa each). Comparison of deduced amino acid 
sequences between ST and SLT has shown the toxins differ by a single amino acid at 
position 45 (threonine in ST and serine in SLT) (Calderwood et al., 1987). The 
structure of the holotoxin has been solved by X-ray crystallography (Fraser et al., 
1994) (Figure 1.2). Each B subunit is folded into one a-helix and 6 ß-strands. The 
helices are surrounded by antiparallel ß-sheets, formed by three strands from each 
pair of neighbouring B subunits. An a-helix at the C-terminus of the A subunit 
penetrates the hydrophobic pore created by the B pentamer. A helical segment of 
hydrophobic residues, Leu 282, Gly 283, Ala 284, Ile 285, Leu 286 and Met 287, 
extends 11A into the 20A pore. Approximately 2000A of the A subunit is buried by 
the B pentamer. Half of this is due to the contact between the C-terminal helix and 
the B subunits (Fraser et al., 1994). 
6 
Figure 1.2 Structure of Shiga toxin a -carbon backbone 
Shiga toxin structure (Fraser et al., 1994), represented as a a-carbon backbone 
drawing with Shiga toxin A-chain in blue. The N- and C-terminus of the A-chain are 
shown in light blue to highlight the location of peptide fusions. 
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The A-chain contains a trypsin-sensitive site, resulting in the generation of two 
fragments Al and A2 that are covalently linked by a disulfide bond. The Al 
fragment carries the N-glycosidase activity and has sequence and structural 
similarity to other members of the RIP family including ricin. Many residues found 
in the active-site are strictly conserved (Calderwood et al., 1987). Residues of the 
A2 fragment make the majority of contacts with the B-chain pentamer along with 
contacts made by a ß-hairpin from Al. Experiments involving the assembly of SLT 
with truncated A-chains suggest that the A2 subunit of SLT is crucial for the 
formation of stable holotoxin (Austin et al., 1994). It has been shown that Golgi- 
located furin is the cellular enzyme responsible for the cleavage of the trypsin - 
sensitive site in several cell types (Garred et al., 1995). Proteolytic cleavage and 
separation of the two A-chain domains is necessary for the full activity of the toxin. 
The crystal structure of ST shows residues 258-262 of A2 lie adjacent to the active 
site cleft and the side chain of methionine 260 is inserted into the active site, 
effectively blocking access to the substrate (Fraser et al., 1994). 
Mutations affecting the catalytic activity of SLT-1 have been studied by placing the 
gene for SLT-1 A-chain under the control of an inducible promoter in 
Saccharomyces cerevisiae (Deresiewicz et al., 1992). Induction of the cloned 
element was lethal to the host and this was the basis for the selection of point 
mutations affecting the activity of SLT-1 A-chain that had lost the ability to kill S. 
cerevisiae. Three aromatic residues were identified in the putative active-site cleft: 
Tyr 77, Tyr 114 and Trp 203, homologous to aromatic residues previously identified 
in ricin (Tyr 80, Tyr 123 and Trp 211). These conserved residues in SLT and ricin 
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(studied as single mutations) decrease the activity of both toxins in the region of 7- 
20 fold (Deresiewicz et al., 1992; Ready et al., 1991; Bradley et al., 1990). 
Other conserved residues have been studied, most notably those that are located at 
the base of the active-site cleft, Glu 177, Ala 178 and Arg 180 in ricin (homologous 
to Glu 167, A1a168 and Arg 170 in SLT-1). In a study by Hovde et al. (1988), the 
glutamic acid residue at position 167 in SLT was selected for mutation as 
carboxylate side-chains are known to be crucial in the catalytic mechanisms of a 
number of enzymes, including other classes of toxins such as diphtheria toxin and 
Pseudomonas exotoxin A. The change of glutamic acid 167 to aspartic acid (The 
SLT mutation used in this study) retains the carboxyl function of the residue but 
alters its spatial position in the SLT A-chain. This mutation caused a 1000-fold 
reduction in activity, when assessed by an assay based on protein synthesis 
inhibition. The corresponding change glutamic acid 177 to aspartic acid in ricin 
decreased catalytic activity 80-fold based on a similar protein synthesis inhibition 
assay (Schlossman et al., 1989). Further structural studies of ricin are discussed 
below. 
1.2.4 Structure of ricin 
The best characterised of the related plant toxins is ricin, a major protein in the 
endosperm of the seed of the castor oil plant, Ricinus communis. Ricin is 
synthesised as a precursor, preproricin, made up of a 35 residue presequence 
followed by the 267 residues of the catalytic A-chain (RTA), a 12 residue linker and 
the 262 residues of the cell-binding B-chain. During biogenesis the signal peptide is 
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cleaved followed by co-translational modifications, including N-glycosylation at 
four sites (two in each of the mature chains) and the formation of four disulphide 
bonds within the B-chain and another which links the mature RTA and B-chain upon 
the subsequent removal of the linker. Mature ricin has a mass of 66kDa (RTA 
30kDa and RTB 29kDa). 
The structure of ricin was determined by X-ray crystallography to a resolution of 
2.8A (Montford et al., 1987) (Figure 1.3). Further structural analyses have been 
published at greater resolutions including RTA resolved at 1.8A by Weston et al., 
(1994) and X-ray analysis of a bound substrate analogue. These have revealed the 
importance of 15 residues in RTA which are essential for association between the 
two chains and along with biochemical analysis, characterised certain residues in the 
active site (refer to section 1.2.3) involved in the catalytic mechanism of the toxin. 
The A-chain contains eight a-helices and eight (3-strands that can be divided into 
three domains. The first domain consists of a six-stranded (3-sheet, the second 
domain is helical in structure, forming the central core of the protein while the third 
domain contains the residues involved in the interface with the B-chain. The 
structure of the A-chain is maintained in the absence of the ricin B-chain (RTB). 
RTB contains two domains originating from gene duplication (with 32% homology), 
each of them having a binding site for carbohydrates such as galactose (Lord et al., 
1994). 
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Figure 1.3 Structure of ricin a -carbon backbone 
Ricin structure (Montford et al., 1987), represented as a a-carbon backbone drawing 
with ricin A-chain in blue and ricin B-chain in green. The N-terminus and C1aI site 
of the A-chain are highlighted in red to depict the location of peptide fusions. 
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1.2.5 Mode of action 
The specific mechanism of action for ricin A-chain (RTA) was elucidated by Endo et 
al. (1987) but has since been shown to operate for all plant RIPs and for the bacterial 
toxins, ST and SLTs. They showed that RTA hydrolytically cleaves a single N- 
glycosidic bond in 28S rRNA, removing a specific adenine residue (A 4324 in rat 
liver 28S rRNA). This adenine residue is present in a highly conserved rRNA 
sequence (in both eukaryotes and prokaryotes) that forms a surface exposed `GAGA' 
tetra-nucleotide loop (Heus and Pardi, 1991; Wool et al., 1992). The kinetics of 
RNA N-glycosidase activity were determined by Endo and Tsurugi (1988) which 
included studies determining the Km for RTA activity on naked 28S rRNA. The data 
indicated that in substrate recognition, there is no absolute requirement for ribosomal 
proteins. 
RIP-depurinated ribosomes are deficient at two stages in protein synthesis. The 
formation of the 80S initiation complex during initiation is slowed down 6-fold and 
the translocation step of the elongation cycle is blocked, detailed in Osborn and 
Hartley (1990). Several type 1 RIPs, including PAP, show activity towards not only 
eukaryotic ribosomes but also prokaryotic ribosomes (Hartley et al., 1991). RTA is 
able to modify naked E. coli 23S rRNA but not whole prokaryotic ribosomes, 
suggesting that prokaryotic ribosomal proteins interfere with access to the rRNA 
substrate. 
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1.3 Toxin entry: Retrograde transport through the secretory pathway 
1.3.1 Introduction 
The structures, mechanism of action and kinetics of RNA glycosidase activity having 
been elucidated, studies in recent years have focused on how AB-toxins gain entry 
into cells. Those toxins that are unable to translocate from endosomes have been 
shown to travel further along the protein transport pathway, in a retrograde direction, 
to the ER (Figure 1.4). 
Recently it has been speculated that these toxins may take advantage of the recently 
discovered ER-associated protein degradation (ERAD) pathway. This pathway 
disposes of misfolded or unassembled proteins in the ER lumen by exporting them, 
via Sec6lp translocons for degradation in the cytosol (Brodsky and McCracken, 
1997). 
Current knowledge of these cellular intoxication processes and retrograde transport 
pathways will be discussed in relation to the toxins in this study, SLT and ricin. 
Other catalytic toxins enter cells by the same mechanisms and reference will be 
made to them where appropriate. 
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Figure 1.4 Retrograde transport of endocytosed toxins 
Schematic representation of retrograde transport of toxins in mammalian cells. Toxins 
bind to receptors on the surface of susceptible cells and enter by endocytosis in a 
clathrin-mediated (ricin, PE, SLT, DT) or clathrin-independent (ricin) manner to reach 
the endosomal system. Endosomes are the site of translocation for toxins such as 
diphtheria toxin (shown in red). Toxins such as Shiga toxin, ricin and Pseudomonas 
exotoxin A (shown in green) are transported to the trans Golgi network (TGN) from 
where they undergo retrograde vesicular transport to the ER, the site of translocation 
for the catalytic A fragment of the toxin. Only a small proportion of the endocytosed 
toxin may take this pathway, the majority is either recycled back to the cell surface 
from endosomes or transported to lysosomes for degradation. 
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1.3.2. Shiga-like toxin-1(SLT) 
1.3.2.1 Cell binding and early uptake 
Shiga toxin (ST) and SLT entry into cells depends on the presence of specific 
glycolipid receptors on the plasma membrane of cells. These were demonstrated to 
be members of the globo-series of glycolipids, composed of short carbohydrate 
chains attached to a ceramide backbone carrying fatty acids of variable length 
(Cohen et äl., 1987). The functional plasma-membrane receptor is 
globotriaosylceramide (Gb3) containing the carbohydrate sequence galactose al-4 
galactoseßl-4 glucose. Receptor synthesis (CD77) is under regulation by tumor 
necrosis factor (TNF), interleukins and butyric acid. A431 cells that are normally 
resistant to ST are sensitised to the toxin by butyric acid treatment (Sandvig et al., 
1992). Support for a glycolipid receptor was verified by the incubation of cells with 
swainsonine and tunicamycin, chemicals known to interfere with both glycosylation 
and processing of glycoproteins. Treatment with these chemicals resulted in no 
decrease in cell sensitivity to ST (Sandvig et al., 1989). 
In the same study Sandvig et al. (1989) reported that ST enters cells in a clathrin- 
dependent manner. Horseradish peroxidase-tagged ST was detected in coated pits by 
electron microscopy. ST is seen to be evenly bound all over the cell surface at low 
temperature but after a short incubation at 37°C, aggregates in clathrin coated pits 
and is endocytosed. Depleting cytosolic K+ or lowering the cytosolic pH, which 
inhibits clathrin-mediated endocytosis, inhibits toxin entry into cells (Sandvig et al., 
1996). It is not known how a glycolipid might act in receptor-mediated endocytosis 
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endocytosis through coated pits, but it may interact with a protein already anchored 
to a pit. In contrast, two other lipid-binding toxins, cholera and tetanus toxin are 
internalised in a clathrin-independent manner. 
Following internalisation, Shiga toxin can be detected in endosomes where it 
colocalizes with the transferrin receptor, a classical marker of early endosomes 
(Johannes et al., 1997). Evidence described below suggests that ST and SLT are 
then transported first to the Golgi stack and then onto the endoplasmic reticulum 
(ER). 
1.3.2.2. Intracellular transport 
There are several different routes that can be followed from the endosome. A large 
fraction of both ST/SLT and ricin is transported to lysosomes for degradation (Van 
Deurs et al., 1988). A large fraction of endocytosed ricin is also recycled to the cell 
surface but this does not seem to be the case for ST/SLT. In experiments where the 
toxin was prebound, the cell surface is cleared of toxin (Sandvig et al., 1989; 1991). 
A relatively small fraction of both ricin and ST/SLT is transported to the TGN and 
onto the Golgi stack. This transport step appears essential for intoxication. Recently 
it has been shown that, uniquely, ST is transported from early endosomes directly to 
the TGN bypassing the usual route from early endosomes via late endosomes to the 
TGN (Johannes et al., 1997). 
For some toxins such as diphtheria, this further transport step is unnecessary, 
translocation into the cytosol occurring directly from acidified endosomes. The low 
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pH in endosomes induces a conformational change in diphtheria that triggers 
translocation of the A-chain (Silverman et al., 1994). Other toxins that translocate 
from endosomes include anthrax, botulinum and tetanus. 
The first demonstration that internalised protein can be transported to the Golgi 
apparatus came when cholera toxin, conjugated to HRP was seen to localise there 
(Joseph et al., 1978). In more extensive experiments, ST conjugated to HRP was 
delivered to the Golgi complex with endocytosed material being examined in 
electron microscope sections (Sandvig et al., 1989; 1991). Using butyric acid- 
sensitised A431 cells treated with ST-HRP conjugates, electron micrographs 
revealed toxin visible in endosomes, lysosomes, throughout the Golgi complex and, 
for the first time, in the ER (Sandvig et al., 1992). The most recent study of ST 
transport visualised ST-HRP conjugates again in the ER of T47D (human breast 
carcinoma) cells. Here the toxin was seen in the ER without the need for butyric 
acid treatment of the cells (Garred et al., 1995). In addition, the isolated ST B-chain, 
again conjugated to HRP, has been shown to be transported back to the ER (Sandvig 
et al., 1994), indicating that this subunit of the toxin is required for the complete 
retrograde transport of SLT to the ER. The visualisation of ST localised to the ER 
by electron microscopy does not signify that this fraction of toxin is physiologically 
significant. However the appearance of ST in the ER of sensitised A431 cells 
correlated well with the acquisition of sensitivity to toxin. This and work with 
brefeldin A suggested that routing to the ER was functionally important. 
Studies with brefeldin A (BFA), known to disrupt Golgi stacks (described in section 
1.3.2.4), have shown that when cells are treated with BFA they are protected against 
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ST and ricin (Sandvig et al., 1991). In addition, in cells incubated with ricin and ST 
at 18-20°C, the delivery of toxin to the Golgi apparatus is blocked. Such cells show 
greatly reduced sensitivity to the toxins (Sandvig et al., 1989). In contrast, 
diphtheria toxin that is translocated from endosomes, remains very potent in both 
BFA-treated cells and in cells incubated at this lower temperature (Sandvig et al., 
1984). 
1.3.2.3 Cellular responses to brefeldin A 
Brefeldin A (BFA) is a fatty acid derivative made by several fungi which induces the 
rapid redistribution of Golgi stacks into the ER. The Golgi fuses with the ER, 
leaving no definable Golgi stack structure. This effect is reversible and removal of 
BFA results in the reformation of the Golgi. Whilst blocking transport of secretory 
proteins out the Golgi, low concentrations of BFA has no effect on cellular processes 
such as endocytosis, lysosomal degradation or protein synthesis (Misumi et al., 
1986). BFA prevents bulk movement of material from the ER to the Golgi system 
(Lippincott-Scwartz et al., 1990) which would include MHC class-1 molecules. It 
follows also that proteins being endocytosed via the trans Golgi network (TGN) to 
the ER will also be blocked by BFA. The BFA-induced reduction in cytotoxicity of 
those RIPs following a retrograde pathway via the Golgi has been well documented 
(Sandvig et al., 1991; Sandvig and van Deurs, 1996). 
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1.3.3 Ricin 
1.3.3.1 Cell binding and early uptake 
The binding of ricin to the surface of target cells is mediated by the B-chain. RTB 
has an affinity for a range of complex oligosaccharides terminating in a1-4 galactose 
and these residues, found on surface-expressed glycoproteins and glycolipids, are 
displayed by a huge number of cell-types and cell-lines. On HeLa cells, for 
example, it is estimated there are 3x107 potential binding sites for ricin. Most 
eukaryotic cells are susceptible to ricin, the most notable exceptions being 
S. Cerevisiae and BHK cells which appear unable to bind toxin at the cell surface. 
Native ricin and RTA also possess the ability to bind and enter cell types by virtue of 
its own carbohydrate side-chains. A limited number of cell lines express mannose 
receptors at the cell surface, allowing ricin and RTA (containing exposed mannose 
residues) to bind to them. Mannose receptor-mediated uptake of ricin has been 
described in both macrophages (Simmons et al., 1986) and rat liver endothelial cells 
(Magnusson et al., 1993). 
Ricin provided some of the first evidence that there is more than one mechanism for 
endocytosis (van Deurs et al., 1987). The binding and internalisation of ricin into 
Vero cells was first visualised using a ricin-gold conjugate (van Deurs et al., 1985). 
Binding of the conjugate, shown to be as efficient as binding of native toxin, was 
visualised in clathrin-coated pits. Other experiments recognised that clathrin- 
independent endocytosis was also involved in the uptake of ricin (Moya et al., 1985). 
Coated pit formation in HEp-2 cells was blocked by hypotonic shock and potassium 
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ion depletion and treated cells then challenged with toxin. In contrast to DT and 
ST/SLT, (which are endocytosed solely by clathrin-coated pits), radiolabelled ricin 
was seen to internalise and kill cells at 50% of that seen in untreated cells. 
Ricin can enter cells via a clathrin-independent mechanism that does not involve 
caveolae (Simpson et al., 1998). The use of sterol binding drugs, such as nystatin, to 
disrupt caveolae formation was shown to have no effect on the sensitivity of cells to 
ricin. The overexpression of dynamin and Rab5, GTPases involved in the regulation 
of clathrin-mediated endocytosis, were also shown by Simpson et al. (1998) to have 
no effect on the intoxication of cells by ricin. The lack of inhibition of ricin toxicity 
in the presence of excess mutant GTPases supports a clathrin-independent 
mechanism of endocytosis. Other results have shown an inhibition of toxicity from 
the overexpression of a mutant dynamin. This observation may not necessarily be 
due to the inhibition of ricin endocytosis but affecting an additional transport step 
from endosomes to the Golgi apparatus (Llorente et al., 1998). 
1.3.3.2 Endocytosis beyond endosomes 
The trafficking of ricin beyond endosomes was initially followed, as for ST/SLT, by 
electron microscopy. Unlike ST, ricin-HRP conjugates were not visualised in the 
ER but did show labelling of the Golgi stacks (van Deurs et al., 1986). Evidence to 
support the theory that like ST/SLT, ricin may also travel from the Golgi complex to 
the ER came from biochemical experiments showing the protection of brefeldin A- 
treated cells against ricin (Yoshida et al.; 1991, Sandvig et al., 1991). In other 
studies, cells overexpressing trans-dominant GTPase mutants, involved in the 
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regulation of Golgi transport and ER export, show significantly reduced ricin 
cytotoxicity (Simpson et al., 1995). 
Experiments with PE mutants provided an explanation of how retrograde transport 
from the Golgi to the ER might occur for PE and also ricin. The last five C-terminus 
residues of the PE A-chain (REDLK) may act as a KDEL-like ER retrieval signal, 
interacting with recirculating KDEL-receptors that normally recycle escaped ER 
resident proteins containing the KDEL motif. Deletions or substitutions predicted to 
prevent interaction with the KDEL receptor (but having no effect on the catalytic 
activity of the toxin) reduce the cytotoxicity of PE (Chaudhary et at., 1990). Indeed 
replacing the REDLK sequence with KDEL produced a mutant even more cytotoxic 
than wild-type PE (Chaudhary et al., 1990). 
Ricin does not possess a KDEL-related sequence but the addition of a KDEL 
retrieval signal to the C-terminus of RTA significantly enhances cytotoxicity (Wales 
et al., 1992). Ricin must therefore encounter recirculating KDEL receptors that are 
predominantly located in the early Golgi. Ricin may undergo retrograde transport 
from the TGN to the ER by binding to a recycling galactosylated component which 
might itself carry a KDEL retrieval signal or interact with another molecule 
containing a KDEL-like motif. The Shiga toxin B-chain does not require the direct 
interaction with a KDEL receptor since the addition of KDEL to this toxin makes no 
difference to the kinetics of entry or to toxin potency (Johannes et al., 1997). It is 
proposed that the glycosphingolipid receptors of ST may be able to carry Shiga toxin 
from the cell surface to the ER themselves. 
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Recently, direct biochemical evidence has shown that endocytosed ricin reaches the 
ER (Rapak et al., 1997). Ricin A-chain was modified to contain a tyrosine sulfation 
site and three potential N-glycosylation sites. Reassociated mutant ricin was 
incubated with cells in the presence of Na235SO4 .A proportion of the holotoxin 
molecules became labelled with radioactive sulphate, indicating that this fraction of 
toxin had been transported through the Golgi stack. Such labelling of ricin could be 
prevented by the treatment of cells with BFA. A fraction of sulphated toxin also 
becomes core glycosylated, conclusively indicating for the first time that transport 
involved passage to the ER. Interestingly, only free glycosylated A-chain was 
subsequently seen in the cytosol, indicating that transport to the ER is necessary for 
translocation into the cytosol. A similar biochemical approach has been used to 
confirm that Shiga B-chain also reaches the ER via the Golgi apparatus (Johannes et 
al., 1997). 
1.4 The ER as the site of toxin translocation into the cytosol 
In recent years it has become apparent that proteins that fail to fold or assemble 
correctly in the ER lumen can be transported the ER membrane to the cytosol where 
they are degraded by proteasomes (Hiller et al., 1996; Werner et al., 1996). The 
mechanisms of this ER-associated protein degradation (ERAD) have been studied 
using both yeast and mammalian cells. 
Human cytomegalovirus (CMV) takes advantage of this export machinery to down 
regulate antigen presentation at the cell surface by class 1 MHC molecules. The 
US 11 gene product of CMV causes the dislocation of the transmembrane MHC class 
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1 heavy chain from the ER membrane to the cytosol and its subsequent degradation 
by proteasomes (Wiertz et al., 1996a). Co-immunoprecipitation studies indicated 
that the MHC class 1 heavy chain in CMV-infected cells may be exported through 
the Sec6lp translocon (Wiertz et al., 1996b) and direct evidence for the involvement 
of Sec6lp has been demonstrated in yeast (Pilon et al., 1997; Plemper et al., 1997). 
If toxins were to be perceived as misfolded or unassembled proteins, they may well 
be able to translocate across the ER membrane by the ERAD pathway. It is unclear 
whether the A and B-chains of toxins such as PE, ST or ricin disslocate in the ER 
before translocation or in the cytosol after the translocation of holotoxin. It may be 
that when the toxins reach the ER lumen, thiol exchange catalyzed by protein 
disulfide isomerase causes dissociation of the disulfide-linked A and B subunits. 
This has been demonstrated to be the case for cholera toxin (Orlandi et al., 1997). 
It is known that dissociation of the toxin A and B-chains exposes hydrophobic 
regions present in the A-chain and in the case of ricin, point mutations in this region 
reduce cytotoxicity but have no effect on the catalytic activity of RTA (Simpson et 
al., 1995). Exposure of this hydrophobic region may promote unfolding of the A- 
chain, leading to possible export to the cytosol by the ERAD system. Evidence 
exists for the partial unfolding of RTA during cell entry (Argent et al., 1994). What 
factors might promote disulfide-bond reduction and unfolding in the ER remain 
unknown. Recent work using Sec6lp mutants in S. Cerevisiae suggests that RTA is 
translocated from the ER to the cytosol via the Sec6lp translocons (Simpson et al., 
unpublished observations). If this proves to be the case, this would be the first 
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example of a native rather than an aberant protein, that becomes ejected from the ER 
lumen to the cytosol. 
If this pathway of entry into the cytosol for certain toxins is correct then some of the 
exported toxin must refold into a biologically active conformation in order to kill the 
cell. To do this, toxin must avoid rapid degradation by proteasomes to which the 
ERAD pathway ultimately leads. Recent evidence suggests that this may be 
achieved by ribosome-induced refolding of a fraction of the dislocated toxin, a 
process which, at the same time, leads to inactivation of the ribosome chaperone 
(Argent, unpublished observations). 
1.5 MHC-restricted antigen recognition 
1.5.1 Overview of MHC class-I and class-II antigen presentation pathways 
The fundamental difference between the two MHC antigen presentation pathways is 
that peptide processing and loading onto MHC class I and class II molecules occurs 
in different intracellular compartments (Cresswell, 1994). MHC class 1 molecules 
bind peptides derived from the processing of cytosolic proteins that are translocated 
from the cytosol into the ER where they form a MHC-peptide complex. Class II 
MHC molecules bind peptides derived from exogenous antigens that are either 
internalized by phagocytosis or enter cells by endocytosis, to be processed within the 
endocytic pathway (Figure 1.5). 
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Figure 1.5 Schematic representation of MHC class-I and class-II 
antigen presentation pathways. 
Basic intracellular pathways of peptide loading onto MHC class-I (I') and class-II 
( I) ) molecules. Class-I associated peptides are generated by proteasomal 
degradation and transported into the ER by TAP (transporter associated with antigen 
processing), where they are loaded onto class-I molecules. The peptide-class-I 
complex is then transported to the cell surface. Class-Il-Ii complexes are transported 
into the endosomal system from the TGN (trans Golgi network). Class-II restricted 
peptides are derived from extracellular proteins internalised via the endocytic 
pathway. Processing of the invariant chain q) and endocytosed proteins occurs in 
endosomes, allowing the formation of peptide-class-II complexes which are then 
transported to the cell surface. Class-I molecules are shown in red, class-II molecules 
in blue. 
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Figure 1.5 Schematic representation of MHC class-I and class-II antigen 
presentation pathways. 
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After their co-translational insertion into the endoplasmic reticulum (ER), MHC 
class 1 molecules are loaded with peptides of typically 8-10 amino acids which are 
generated in the cytosol by proteasomal degradation of endogenously derived 
proteins. Following peptide transport to the ER by transporters associated with 
antigen processing (TAPs) in the ER membrane, specific peptides become bound to 
MHC class 1 molecules, which are then secreted to the plasma membrane surface. 
Cytotoxic T lymphocytes (CTL) are activated following recognition of a foreign 
peptide in association with MHC class 1 molecules, by an antigen-specific T cell 
receptor (TCR). Activated CTLs lyse the infected cell, exposing the pathogen to the 
humoral immune system, which the activated CTLs enhance by the secretion of a 
number of cytokines. Activated CTLs then proliferate to clear other infected cells 
and differentiate to provide a set of long-lived memory cells, able to respond at a 
heightened level to subsequent infection by the pathogen. 
In contrast, processing of proteins destined to generate epitopes for MHC class-II 
binding occurs in endosomes. A number of endoproteases and exopeptidases are 
known to be expressed within the endosomes/lysosomes of antigen presenting cells 
(Chapman, 1998). Another role of these endosomal proteolytic enzymes is the 
cleavage of a nonpolymorphic invariant chain (Ii) that associates with newly 
synthesised MHC class-II a and 0-chains in the ER. The invariant chain acts as a 
chaperone, promoting the proper assembly of MHC class-II dimers and preventing 
the premature loading of ER-resident peptides. A lumenal domain within the 
invariant chain termed CLIP (Class-II associated Invariant Peptide) protects the 
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peptide-binding groove. MHC class-II dimers associate with the chaperone to form 
trimers, which themselves associate to form a trimer resulting in a nanomeric 
complex (Cresswell, 1994). Correct trafficking of MHC class-II complexes is 
dependent on the invariant chain. Trafficking to endosomes requires N-terminal Ii 
cytoplasmic sequences. The rapid degradation of the invariant chain is necessary for 
the endosomal loading of peptides and rapid transport to the cell surface (Brachet et 
al., 1997). If this degradation is delayed, MHC class-II: Ii complexes are transported 
to lysosomes, from where they move slowly to the cell surface. 
Although a number of major proteases, have been implicated in the processing of the 
invariant chain, selective irreversible inhibition of a minor protease, cathepsin S, 
blocks the complete processing of Ii and the generation of the CLIP fragment 
therefore indicating an important role for this enzyme (Reise et al., 1996). 
Degradation of Ii begins at the luminal C-terminal domain, required for the 
association of nanomeric complexes (Bijlmakers et al., 1994), promoting their 
dissociation to MHC class-II: Ii heterotrimers. Proteolytic processing of Ii results in 
the generation of a MHC class-II: CLIP complex, able to interact with a 
nonpolymorphic MHC-like dimer termed HLA-DM which catalyses the dissociation 
of CLIP from MHC class-II molecules, enabling peptide loading of the empty 
peptide-binding MHC groove (Sloan et al., 1995). 
Once bound to MHC class-II dimers, the protein fragments can be repeatedly nicked 
by proteases, the core peptide being protected from proteolysis by the MHC-binding 
groove itself. Unlike MHC class-I molecules, the MHC class-II heterodimers may 
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therefore aid in the generation of antigenic diversity to a protein by participating in 
the processing of the antigens (Deng et al., 1993). 
MHC class-Il-peptide complexes are then transported to the plasma membrane 
where they can be recognised by CD4+ T helper cells. This leads to the production 
of a number of cytokines, activating B-cells to produce antibodies and signalling for 
activated CTLs to differentiate and provide a set of long-lived memory cells. 
The two MHC pathways are not entirely discrete and there are exceptions to the rule. 
Endogenous peptides derived from cytosolic proteins, generated in the ER can also 
associate with class-II molecules (Nuchtern et al., 1990; Weiss et al., 1991). 
Similarly epitopes generated from phagocytosed proteins may gain access to the 
MHC class 1 pathway (Watts, 1997). In transgenic mice, CD8+ T cells can also 
recognize peptides in association with MHC class-II molecules (Kirberg et al., 
1994). 
1.5.2 MHC class-I and class-II structures 
The major histocompatibility complex is a collection of genes within a long 
continuous stretch of DNA on chromosome 6 in humans and on chromosome 17 in 
mice. The region is highly polymorphic, many alleles existing at each locus, and 
encodes for MHC class-I and class-II molecules including a number of soluble serum 
proteins and enzymes associated with the immune process. 
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MHC class-I molecules consist of a large polymorphic glycoprotein a-chain (45kDa) 
non-covalently associated with a smaller invariant ß2--microglobulin protein (12kDa) 
(Figure 1.6). The a-chain is a transmembrane glycoprotein, containing a 
hydrophobic transmembrane segment, a hydrophilic cytoplasmic tail and three 
external domains (al, a2 and CO. The al and a2 domains interact to form a deep 
groove of eight antiparallel ß strands spanned by two long a-helical regions, which 
is the peptide-binding site. The peptide-binding site is closed at both ends, limiting 
the size of peptide that can be accommodated. 
MHC class-II molecules share a similar structure to MHC class-1 molecules, being 
membrane-bound glycoproteins that contain external domains, a transmembrane 
segment and a cytoplasmic anchor. MHC class-II molecules contain an a and P- 
chain that associate non-covalently, the al and ßl domains forming the peptide- 
binding region (Figure 1.7). 
The peptide-binding groove of MHC class-I molecules restricts peptide lengths to 8- 
10 residues. Peptides that have been eluted and sequenced from a variety of human 
and mouse class-I molecules are listed in Table I. I. The carboxyl terminus and the 
second residue from the amino terminus are conserved anchor residues, interacting 
with invariant pockets in the binding groove. Over the majority of the binding 
groove there is considerable flexibility, MHC class-I molecules being able to bind a 
range of peptides. Water molecules have been found to fit around the spaces 
between the binding groove and peptide, optimising the interaction between MHC 
and peptide (Smith et al., 1996). 
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side view 
top view 
Figure 1.6 Structure of human class-1 molecule HLA B35 with bound 
HIV-2 gag peptide. 
Ribbon diagram of human class-1 molecule complexed with HIV-2 gag peptide 
(single letter code-TPYDINQML) (Smith et al., 1996) The class-1 heavy chain is 
shown in blue with 02microglobulin chain in green. The peptide bound in the class-1 
groove is highlighted in red. 
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side view 
top view 
Figure 1.7 Structure of human class-II molecule HLA I-AD with bound influenza 
haemagglutinin peptide. 
Ribbon diagram of mouse class-Il molecule complexed with influenza 
haemagglutinin peptide (single letter code-PVSKMRMATPLMEA) (Scott et al., 
1998). The a-chain is shown in blue, the ß-chain in green. The peptide bound in the 
class-II groove is highlighted in red. 
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In contrast the MHC class-II peptide-binding groove is more open in structure, 
allowing a variation in length of bound peptides (13-18 residues) but containing 
typically nine residues of conserved secondary structure, bound within the class-II 
groove with additional, relatively free amino and carboxyl-terminal residues 
(Jardetzky et al., 1996). Thus predictions of potential T-cell epitopes in antigens of 
known sequence can be made using known binding motifs. 
1.5.3 Antigen-presenting cells 
While nearly all tissues express MHC class-I molecules, the expression of class-II 
molecules is generally restricted to certain cell types, including B lymphocytes, 
dentritic cells from various tissues and some populations of mononuclear 
phagocytes. These particular cells can be characterised as professional antigen- 
presenting cells (APCs), describing cells that both present MHC-peptide and express 
surface proteins that interact with receptors on the T cell to generate a second signal 
(Mellman et al., 1998). The second signal, which is non-specific, is required to 
initiate the T cell response, stabilising the interaction between the T cell and APC 
(Schwartz et al., 1992). `Amateur' APCs lack the ability to elicit `signal 2' and are 
recognized only by previously activated T cells. It is possible that amateur APCs 
may present peptide to T cells that subsequently become activated by a professional 
APC recruited to the site of infection (Tighe et al., 1998). 
33 
Class-1 molecule 
/epitope 
Conserved 
residues 
/peptide 
sequence 
Class-1 molecule 
/epitope 
Conserved 
residues 
/peptide 
sequence 
Human 
HLA A2 2C HLA All 2C 
Flu Ma 56-68 GILGFVFTL EBV EBNA4 IVTDFSVIK 
HTLV1Tax 11-19 SLFGYPVYV HIV gag 325-333 AIFQSSMTK 
HCMV gB 619-628 IAGNSAYEYV HIV nef 74-82 PLRPMITYK 
HBV Ncp 18-27 FLPSDFFPSV p53 343-351 ELNEALELK 
HIV-1 pol 476-484 ILKEPVHGV 
HIV-1 gag 77-85 SLYNTVATL 
Mouse 
HLA B35 2C H-2Db 25C 
PF cp26 368-375 KPKDELDY Flu NP 366-374 ASNENMDAM 
PF 1s8 1850-1857 KPNDKSLY SV40-T 207-215 AINNYAQKL 
HIV-1 nef 74-81 VPLRPMTY HPV E7 47-57 RAHYNIVTF 
HIV-2 gag 245-253 NPVPVGNIY LCMVGPI KAVYNFATC 
CMV pp65 123-131 IPSINVHHY LCMVNP FQPQNGCFI 
HLA B8 35C H-2Kb 25C 
Flu NP 386-394 ELRSRYWAI Ovalbumin257-264 SIINFEKL 
EBV EBNA3 339-347 FLRGRAYGI VSV NP 53-60 RGYVYQGL 
HIV gag p17 24-32 GGKKKYKLK SV NP 324-332 FAPGNYPAL 
HIV pol 185-193 DPKVKQWPL Insulin 31-39 CGSHDVEAL 
HIV gag 24 331-339 DCKTILKAL 
Table 1.1 Sequences of MHC class-1 binding peptide epitopes 
A selection of class-1 binding epitopes are listed, together with the peptide sequence 
and conserved anchor residues (emboldened). One anchor residue is always at the 
carboxyl- terminus (denoted C), a second anchor residue is commonly found at 
postion 2 but may be present at position 3 or 5 of the peptide. 
Key: Flu, influenza A virus; SV, Sendai virus; HPV, human papilloma virus; VSV, 
vesicular stomatis virus; PF, Plasmodium falciparum; LCMV, lymphocytic 
choriomeningitis; HTLV, human T cell leukaemia; HCMV, human cytomegalovirus; 
HBV, hepatitis B virus; HIV, human immunodeficiency virus; EBV, Epstein-Barr 
virus. 
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1.6 MHC class-I presentation pathway 
1.6.1 Mechanisms of MHC class-I restricted antigen processing 
The majority of class-I restricted antigen processing is attributed to the activity of 
proteasomes, large multicatalytic cylindrical proteases which are located in the 
cytosol and nucleoplasm (Figure 1.8). They are the major non-lysosomal protein 
degradation enzymes in eukaryotic cells. The core 20S proteasome consists of four 
seven-membered rings, with the catalytic sites centred in the central cavity. 
Regulatory complexes (19S) can bind to the ends of the cylinder to form 26S 
proteasomes. The 26S proteasomes recognise ubiquitinated substrates by their 19S 
subunit but can also degrade non-ubiquitinated proteins by ATP-dependent 
mechanisms (Rivett, 1998). 
The evidence for proteasome involvement in antigen presentation came about from 
the use of peptide aldehydes that inhibited the proteolytic activities of proteasomes 
(as well as other proteases such as the cytosolic cysteine protease calpain) and 
blocked the presentation of antigens introduced into the cytosol by MHC class-1 
molecules (Rock et al., 1994; Harding et al., 1995; Hughes et al., 1996). 
Several types of inhibitors of the proteasome have been identified. Peptide 
aldehydes are reversible substrate analogues and transition-state inhibitors of the 
proteasome and also certain lysosomal cysteine proteases and calpains. Lactacystin 
is more specific than peptide aldehydes, acting again as a pseudo-substrate. It shows 
higher specificity but can also inhibit lysosomal cathepsin A. Lactacystin has been 
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Figure 1.8 Proteasome association with regulatory complexes in animal cells. 
The core 20S proteasomes has a hollow cylindrical structure, the catalytic sites 
contained inside the central cavity. Regulatory complexes can bind to both ends of 
the cylinder. The I IS regulator (PA28) is inducible by interferon-y and has been 
implicated in antigen processing, while the binding of 19S regulatory complexes 
results in the formation of the 26S proteasome, required for ubiquitin-dependent 
protein degradation (and also for the ATP-dependent degradation of some non- 
ubiquitinated proteins). 
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shown to inhibit proteasome function by linking covalently to the hydroxyl groups 
on the active site of the ß subunits, inactivating chymotryptic and tryptic-like 
activities. A new class of reversible proteasome inhibitors now exists, containing a 
boronate group, that do not inhibit other cellular proteases and bind with a higher 
potency. 
Lactacystin was shown to block the presentation of certain epitopes in human and 
murine cells (Cerundolo et al., 1997) but only partially block or have no affect on 
others (Vinitsky et al., 1997). This suggests the involvement of non proteasomal 
cytosolic proteases in the generation of MHC class-I binding peptides. Research into 
the adaption of mammalian cells with inhibitor- induced inactivated proteasomes, 
suggests that other proteolytic systems can compensate for the loss of proteasomal 
activity (Glas et al., 1998). 
Other implications into the role of proteasomes in antigen processing came about 
from the recognition that two proteasomal subunits (termed LMP2 and LMP7) are 
encoded for by genes located in the MHC (Brown et al., 1991) and that LMP-2 and 
LMP-7-deficient mice show defects in the processing of certain antigenic peptides 
(van Kaer et al., 1994; Fehling et al., 1994). Both LMP2 and LMP7 replace two 
constitutive proteasome subunits upon induction by interferon-y. Incorporation of 
these subunits into proteasomes has been reported to alter the substrate specificity of 
the proteasome (Driscoll et al., 1993), with preference to the generation of peptides 
suitable for antigen presentation. IFN-y stimulation was reported to reduce the 
generation of peptides with acidic carboxy-terminal residues and to favour the 
generation of peptides with hydrophobic or basic carboxyl-termini (Gaczynska et al., 
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1993; 1994) although other groups have reported different changes (Boes et al., 
1994; Kuckelhorn et al., 1995). 
Another IFN- y inducible subunit has been implicated with antigen processing. The 
20S proteasome can associate at both ends with the 11S (PA28) activator complex 
enhancing the cleavage of short peptide substrates in vitro and the class-I mediated 
presentation of two viral epitopes in vivo (Groettrup et al., 1996). Complexes 
containing these IFN-y inducible subunits have been termed immunoproteasomes 
(Tanaka et al., 1997). PA28 replaces the 19S regulatory complex of the 26S 
proteasome that is responsible for the recognition and degradation of ubiquitinated 
substrates. 
The involvement of the ubiquitin pathway in antigen presentation is inconclusive at 
the present. Initial observations by Townsend et al,. (1988) suggested that ubiquitin 
tagging enhanced the presentation of an influenza nucleoprotein epitope, other work 
has found antigen presentation to be ubiquitin-independent (Michalek et al., 1996). 
The distribution of immunoproteasomes in the cytosol has been investigated by 
Rivett et al., (1998) using antibodies against LMP2 and LMP7. Proteasomes 
containing these subunits have been found to localise around the ER, suggesting that 
in addition to altering the catalytic abilities of proteasomes, LMP2 and LMP7 may 
target immunoproteasomes to the ER. It is still not known how peptides that are 
released from proteasomes are directed to TAP peptide transporters in the ER 
membrane and without degradation. Having found TAP to be localised near the ER, 
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it may be that immunoproteasomes can bind directly to TAP for efficient transport of 
peptides. 
1.6.2 Transporters associated with antigen processing (TAPs) 
Transporters associated with antigen processing (TAPs) are noncovalent complexes 
of two homologous subunits TAP1 and TAP2 that belong to the superfamily of ATP- 
binding cassette transporters (Figure 1.9a). Like the proteasomal subunits 
LMP2/LMP7 and PA28, the TAP subunits are encoded in the MHC. Each TAP 
subunit has an N-terminal hydrophobic region with multiple transmembrane 
spanning domains and a cytosolic C-terminal ATP-binding domain. 
Studies demonstrating the ability of TAP to translocate peptides across the ER 
membrane, have involved the use of TAP-containing microsomes or cells with 
permeabilized plasma membranes to follow the fate of radiolabelled peptides 
(Neefjes et al., 1994). By radiolabeling with photoactivatable peptides containing 
crosslinkers, it has been established that both TAP1 and TAP2 subunits contribute to 
peptide binding (Nijenhuis et al., 1996) which, unlike peptide translocation, is ATP 
independent. 
TAP transporters preferentially transport peptides of 8-12 residues, the sequence 
specificity of these peptides varying between species (Neefjes et al., 1995). The 
transport specificity of TAP meets the requirements needed for the binding of 
39 
A) Schematic representation of TAP 1 /TAP2 heterodimer. 
8-10 transmembrane domains (per TAP monomer) 
-ýýTAP1 
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B) Maturation of human class-1 molecules in the ER. 
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Figure 1.9 Peptide assembly with MHC class-1 molecules 
Hypothetical sketches of the TAP transporter and the interaction of a number of 
chaperones in MHC class-l-peptide assembly A) Cross-section of TAP heterodimer 
spanning the ER membrane. Eight to ten transmembrane segments (per TAP 
monomer) are predicted with the ATP-binding domains extending into the cytosol. 
B) Newly synthesised class-1 heavy chains initially associate with calnexin which 
promotes their assembly with ß2 microglobulin light chains. Empty class-1 
heterodimers then associate with calreticulin (the soluble homologue of calnexin), 
Erp57 and form a complex with tapasin. Tapasin enables empty class-1 heterodimers 
to associate with TAP. Upon loading of peptide, the MHC class-l-peptide complexes 
are released for transportation to the cell surface. 
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peptides by MHC class-I molecules, selectively transporting peptides suitable for 
class-1 antigen presentation. 
The physical interaction of the MHC complex with TAP has been demonstrated by 
Suh et al., (1996). They showed that the TAP! subunit alone is sufficient for this 
interaction and that the addition of class-I binding peptides to permeabilised cells or 
lysates releases MHC class-I molecules from TAP. This indicates that association 
with TAP and peptide loading is a stage in the maturation of the MHC class-I 
complex. Other components have been found to transiently associate with MHC 
class-! molecules and aid in the assembly of peptide-loaded MHC complexes, their 
role in this process is described below. 
1.6.3 MHC-peptide assembly in the ER 
Molecular chaperones function in the ER to associate with newly synthesised 
proteins and assist in the correct folding. A number of chaperones are involved in 
the maturation of MHC-peptide complexes (Figure 1.9b). Calnexin is the first 
chaperone that class-I heavy chains encounter after their biosynthesis in the ER 
membrane (Degen et al., 1992). Calnexin is a type-I membrane protein with its 
substrate-binding domain located in the ER. Calnexin facilitates the folding and 
disulfide bridge formation of heavy chains, promoting its association with 12- 
microglobulin. Calnexin is then replaced by its soluble homologue, calreticulin 
(calreticulin showing homology to the luminal domain of calnexin). It has been 
shown that calreticulin then remains associated with the heavy chain-(32m 
heterodimers during the transient interaction with TAP (Sadasivan et al., 1996). 
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A further glycoprotein (48kDa) was found in a complex with TAP, MHC and 
calreticulin, termed tapasin (Sadasivan et al., 1996). Tapasin may form a bridge 
between heavy chains and TAP, being able to bind each independently. The affinity 
of heavy chains for the TAP-tapasin complex has been found to differ between MHC 
class-1 allelles (Neisig et al., 1996). The latest protein that has been identified as a 
component of this complex is ERp57 (Hughes et al., 1998). The role of tapasin, 
calreticulin and Erp57 may be to keep the MHC class-1 complex in a conformation 
state ready for peptide binding and to retain the complex in the ER. Peptide binding 
then causes the dissociation of these accessory proteins. 
1.6.4 Processing of MHC class-I restricted antigens in the ER 
It is currently thought that cytosolic proteasomal degradation is the major source of 
peptides for MHC class-I binding (section 1.7.1). This has been concluded from a 
number of observations that show proteasome-specific inhibitors reduce the level of 
antigen presentation to CTLs. In addition, cell mutants lacking TAP transporters for 
peptide translocation into the ER have reduced levels of class-I molecules at the cell- 
surface indicating that the majority of antigenic peptides are generated in the cytosol. 
However there are examples of alternative antigen processing, suggesting that 
degradation may also take place in the ER. Peptides associated with class-1 
molecules in TAP-negative cells, have been found to be derived from signal 
sequences that have direct access to the ER and are liberated by signal peptidase. 
Secretory and transmembrane proteins, that are co-translationally inserted into the 
ER, are known to generate epitopes in TAP-negative cells although, several of these 
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have been shown to have been translocated from the ER by Sec6lp (section 1.2) and 
processed in the cytosol (Mosre et al., 1998). 
Studies with minigenes encoding peptide epitope precursors, preceded by the 
influenza hemagglutinin ER translocation sequence, have shown that processing of 
polypeptides of at least 40 residues can occur in the ER of TAP-negative cell-lines 
but that the proteolysis of larger proteins is limited (Elliot et al., 1995). The release 
of epitopes from the C-terminus is more efficient than from the N-terminus of such 
precursors processed in the ER, suggesting the involvement of N-aminopeptidases 
(Snyder et al., 1997). 
These studies indicate that processing of MHC class-I restricted antigens can occur 
in a proteasome-independent manner and that alternative processing mechanisms 
may exist in the ER. 
1.6.5 Cell surface presentation of MHC-peptide complexes 
It is generally assumed that once the MHC-peptide complex leaves the ER, 
progression to the cell surface is rapid (Jackson et al., 1994). Studies with 
mammalian cells that overexpress MHC class-I heavy chains and 02-microglobulin 
have found that the expression of MHC class-I molecules at the cell surface may be 
regulated (Joyce, 1997). They found that only 2 to 20% of the overexpressed (50- 
fold) class-I molecules were stably expressed at the plasma membrane even though 
the majority formed complete MHC-peptide complexes. Almost all of the MHC 
class-I molecules became sialylated, indicating trafficking as far as the Golgi. Their 
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regulation at the cell surface may be achieved by the rapid internalisation and 
recycling of class-I molecules from, and back to the plasma membrane. 
Alternatively, sorting may occur in the TGN (Joyce, 1997). 
1.6.6 Cellular responses to interferon-y 
The elevation of MHC class-1 molecules expressed on the cell surface involves the 
upregulation of many genes, most encoded in the MHC, that play a role in the 
antigen presentation pathway. The expression of the ß2m and MHC heavy chain 
genes are upregulated by IFN-y as well as by IFN-a/ß and TNF-a. 
The transporter associated with antigen processing (TAP) is a heterodimeric member 
of the ATP-binding cassette transporter family and is essential for the transport of 
peptides from the cytosol to the ER for loading onto MHC class 1 molecules. Both 
genes encoding the two subunits of TAP (TAP 1 and TAP 2) map to the class II 
region of the MHC and are inducible by IFN-y. 
The proteasome ß-subunits LMP-2 and LMP-7 both map in the class II region of the 
MHC, in close proximity to the TAP genes. The replacement of constitutive 0- 
subunits in the proteasome with IFN-y inducible ß-subunits (including MECL-1 
which is encoded elsewhere in the genome) results in the modification of proteolytic 
cleavage preference, increasing the suitability of peptides for class 1 loading. The 
proteasome activator (PA28), which enhances the yield of peptides of a size and 
structure optimal for TAP transport and class 1 loading is also upregulated by IFN-y. 
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ER luminal proteins have also been found to be upregulated by IFN-y. Tapasin, 
mapping in or near the MHC, is required for the normal assembly and loading of 
MHC class 1 molecules. A number of chaperones including gp96 have been 
implicated in taking a role in protecting peptides entering the ER from degradation 
and helping their loading onto MHC class 1 molecules. 
1.7 Towards development of CD8+T-cell vaccines 
Activated CTL are an important component of the protective and therapeutic 
immune response to viral infections and tumours. A number of approaches to 
generate safe CTL-based vaccines are being studied. Direct immunisation, with a 
viral protein or synthetic peptide tends to lead to antigen endocytosis and association 
with MHC class-II complexes. Live or attenuated viral vaccines, that are processed 
and presented by the MHC class-I pathway, are potentially pathogenic and a risk to 
the recipient. The reversion of an attenuated vaccine strain to a virulent phenotype is 
particularly important when considering pathogens such as HIV. 
These safety issues have forced the development of subunit or inactivated virus 
vaccines, self proteins expressing antigenic peptide or the delivery of exogenous 
proteins (for presentation by MHC class-1 molecules) by liposome complexes or 
synthetic lipopeptides (reviewed by Bona et al., 1998). In many cases, these 
vaccines have not elicited the necessary humoral, cellular and mucosal response, 
necessary for long-term memory andto confer life-long protection in immunized 
individuals. 
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However, promising vaccine vectors have been developed in recent years that are 
now reaching the stage of clinical trials. Plasmid DNA-based vaccines have been 
shown to elicit strong humoral and cellular immune responses in rodents and non- 
human primates. DNA, encoding antigens under the control of a eukaryotic 
promoter, is adhered to gold particles to increase its mass before being injected 
through the skin using a helium driven gun to accelerate the particles. The DNA is 
incorporated into the skin's antigen presenting cells, which produce antigenic 
proteins that illicit an immune response (PowderJect Pharmaceuticals, UK). 
This technology has been combined with another promising vaccine vehicle 
candidate, recombinant vaccinia viruses expressing antigens derived from pathogens. 
Prime-boost immunization strategies in mice have been carried out, comparing 
combinations of recombinant vaccinia virus strains and plasmid DNA. The modified 
virus Ankara (MVA) strain of vaccinia has been attenuated such that MVA is 
replication-restricted (losing 31kb of DNA) and has been used safely on humans 
during a smallpox immunization program (Mayr et al., 1978). 
Using plasmid priming and recombinant MVA boosting in mice, complete protection 
against Plasmodium berghei, the rodent virus model for malaria, has been observed 
(Schneider et al., 1998). This protection was associated with high levels of activated 
CTLs in the spleen and was dependent on the specific order of vaccine delivery 
(DNA priming and MVA boost). A similar vaccination programme has been used to 
enhance the induction of HIV-specific CTL in mice (Hanke et al., 1999). 
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CD8+ T cell vaccination is only suitable against viral infections or intracellular 
pathogens known to raise a strong CTL response in their host. Pathogens known to 
raise such a response (and have a global impact on health) include HIV, malaria (as 
noted above), rotavirus, Ebola virus (Xu et al., 1998) and the intracellular bacterial 
pathogen, Mycobacterium tuberculosis (Kaufmann, 1999). In contrast, influenza 
virus tends to raise a humoral antibody response to infection. 
In addition to viral vaccines, CD8+ T cell immunotherapy has been successfully used 
to elicit anti-tumour responses in certain cancers that are poor stimulators of an 
immune response, or that may have induced tolerance towards tumour cells. As well 
as the use of recombinant viral and bacterial vaccines (adenovirus, vaccinia and 
Listeria monocytogenes are common vectors), dendritic cell (DC)- based vaccines 
are under investigation. Autologous DCs, pulsed with tumour lysate or MHC class-1 
restricted melanoma peptides are used as antigen carriers for tumour vaccination. An 
alternative approach to the priming of DCs with peptides is to transfect cells with 
tumour-derived RNA, an advantage being that RNA encodes multiple epitopes for 
many HLA alleles (Smita et al., 1998). 
T-cell based vaccines have also been shown to suppress certain autoimmune diseases 
and inhibit allergic responses, involving the administration of increased doses of 
allergen- encoding vaccines to induce T cell tolerance (reviewed by Tighe et al., 
1998). 
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1.8 Aims of project 
To develop a model system whereby an antigenic peptide fused to a `carrier' toxin is 
delivered to MHC class-I molecules assembled in the ER. This would lead to the 
subsequent presentation of the intracellular peptide at the cell surface and the 
elicitation of an antigen-specific cytotoxic T lymphocyte (CTL) response. 
The toxins used , Shiga-like toxin-1 from E. coli 0157: H7 (SLT) and ricin, are 
members of a family of ribosome inactivating proteins (RIPs), that undergo 
retrograde vesicular transport from the cell surface to the ER, before translocating 
into the cytosol. To be useful, disarmed toxins with defective or deleted catalytic 
domains must be utilised in order that target cells are not destroyed in the process of 
peptide delivery. For SLT, this was achieved by using a mutant with an active site 
mutation (E167D). The activity of E167D SLT, purified to homogeneity from E. coli 
by receptor-ligand based chromatography, was assessed by in vitro ribosome- 
inactivation assays and in vivo cytotoxicity comparisons with wild-type SLT. The 
SLT A chain was genetically fused with a well defined nonamer peptide derived 
from influenza virus Matrix protein (Ma, 58-66), positioned at either the N- or C- 
terminus of the toxin. 
The active-site mutations R180H and E177D in ricin were expressed both 
individually and as a double mutant in an attempt to engineer a holotoxin completely 
devoid of activity. Influenza Matrix peptide 58-66 (Ma) and influenza 
Nucleoprotein 366-374 (NP) were placed at the N-terminus of RTA. NP was also 
placed within an external loop (residue 113-114), accessible by a Cla 1 site to study 
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the possible effect of positioning of the peptide within the toxin. The toxin fusion 
proteins constructed are shown schematically in Figure 1.10. 
It is now evident that both SLT and ricin undergo retrograde transport from the cell 
surface to the ER (described in section 1.3). Recent evidence suggests that the toxins 
may then exploit the ER export machinery normally associated with the ejection of 
aberrantly folded ER proteins to the cytosol for degradation by proteasomes. 
Processing of the toxin chimeras may therefore occur at two stages during this 
progression either directly in the ER by ER-resident proteases or in the cytosol. 
Once in the cytosol the toxin chimeras may follow the conventional proteasome 
degradation pathway or be processed by other cytosolic proteases. The intracellular 
routing of the novel wtSLT-peptide fusion proteins and the location of peptide 
loading of MHC class-1 molecules were investigated by treating cells with the Golgi 
stack-disrupting agent brefeldin A. Cells were also treated with the proteasome- 
specific inhibitor lactacystin to examine the processing requirements of the SLT- 
peptide fusions. 
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Figure 1.10 Schematic representation of toxin peptide fusion proteins constructed 
in this study 
The catalytic A-chain is shown in grey (A , refers to a catalytic site mutation), the 
cell-binding B-chain in green. The position of the peptide is denoted by the zig-zag 
and is either influenza Matrix peptide 58-66 (Ma) or influenza Nucleoprotein 366- 
374 (NP). Disulfide bonds that covalently link a trypsin-sensitive site or two 
fragments are labelled. 
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CHAPTER 2 
MATERIALS AND METHODS 
Chapter 2 
Materials and Methods 
2.1 Suppliers and reagents 
2.1.1 Suppliers 
The majority of reagents used were obtained from BDH Chemicals Ltd (UK), Fisons 
(USA) or Sigma (UK) and were of analytical grade if available. Suppliers of other 
reagents are listed below. 
Aldrich (USA) 
Tween 20 
Amersham (UK) 
HybondTMC nitrocellulose, HybondTMN nitrocellulose, a_[35S] dATP (1000Ci/mmol), 
[35S] methionine (3000Ci/mmol), y-[32P]-ATP (5000Ci/mmol). 
Bio 101 inc. (USA) 
Geneclean II kit. 
Boehringer Mannheim (UK) 
Adenosine triphosphate, Sequencing grade trypsin, Protease inhibitor cocktail tablets. 
Calbiochem (UK) 
lactacystin 
Chivers and Sons Ltd. (UK) 
Dried skimmed milk powder. 
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Difco (USA) 
Bacto-agar, bacto-tryptone. 
Gibco BRL (USA) 
RPMI 1640 medium, Dulbecco's Modified Eagle's medium, Geneticin G418 
Sulphate, trypsin-EDTA solution, agarose, restriction enzymes and REactTM buffers, 
T4 DNA ligase, T4 polynucleotide kinase, medium-range molecular weight markers. 
Inland Laboratories (USA) 
Ricin-B-chain 
Johnson-Matthey (UK) 
Silver nitrate 
Kodak (UK) 
LX24 developer, Unifix 
NBL Gene Sciences Ltd. (USA) 
40% Acrylamide-Bisacrylamide 
Oxoid (UK) 
Yeast extract. 
Pharmacia Biotech (Sweden) 
CM-Sepharose, DEAE-Sephacel, PD-10 desalting column. 
Polaroid (UK) 
665/667 photographic film. 
Promega (USA) 
BCIP, NBT, rabbit reticulocyte lysate. 
Qiagen (Germany) 
QlAprep spin plasmid kit, QlAprep, Maxi plasmid kit. 
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Sigma Immunochemicals 
Donkey anti-sheep antibody (conjugated to alkaline phosphatase), goat anti-mouse 
IgG Fab-specific FITC-conjugate antibody. 
USB(USA) 
Sequenase T7 DNA polymerase. 
Whatman (UK) 
3MM chromatography paper 
Zenecca Pharmaceuticals(UK) 
Recombinant ricin-A chain 
2.1.2 Standard reagents 
Standard solutions and media were prepared as in Sambrook et al,. (1989). 
Phosphate-buffered saline (PBS) (137mM sodium chloride, 0.27mM potassium 
chloride, 10.4mM disodium hydrogen phosphate, 1.8mM potassium dihydrogen 
phosphate). 
2.1.3 Aniline reagent 
Aniline was prepared from aniline which had been distilled twice, 1m1 of this was 
mixed with 7ml of distilled water and 0.5m1 glacial acetic acid in a sterile glass 
universal. The pH of the aniline was adjusted to pH4.5 by the addition of glacial 
acetic acid drop-wise and the final volume made up to 11m1 with water. Aniline 
reagent was stored in the dark at 4°C. 
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2.2 Growth and Maintenance of Cells 
2.2.1 Maintenance of Escherichia coli Strains 
The genotype of the strains of E. coli used were: 
TG2 supE hsd A5 thi p(lac proAB) A(srl-recA)306:: Tn1O(tet r) 
F[traD36 proAB+ 1ac19 lacZ AM15] 
71-18 supE thi A(lac-proAB) F'[proAB+lac1QlacZAM15 
E. coli strains JM109, TG2 and 71-18 were maintained on Luria-Bertani (LB) plates 
(10g/l bacto-tryptone, 5g/1 yeast extract, 10g/1 sodium chloride, 2% (w/v) bacto-agar) 
by streaking and subsequent incubation at 37°C overnight. 
Maintenance of Mammalian Tissue Culture Cells 
The mammalian cell lines used were as follows: 
HeLa human cervix epitheloid carcinoma 
HeLa-A2 HeLa cells stably transformed with an HLA-A2 haplotype 
[stably transformed using the pcdNA3.1/HIS XpressTM 
expression system (Invitrogen, UK)] 
Vero African Green Monkey kidney fibroblast 
Skmel-29 human melanoma, HLA-A2 haplotype 
L murine fibroblast, H2-Db haplotype 
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HeLa and Vero cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 5% heat inactivated foetal calf serum, 2mM glutamine, 50 IU/ml 
penicillin, 300pg/ml streptomycin. L06 were grown in DMEM supplemented as 
above with 10% heat inactivated foetal calf serum. SKmel-29 cells were grown in 
RPMI 1640 medium (supplemented with 10% heat inactivated foetal calf serum, 
2mM glutamine, 50 IU/ml penicillin, 300pg/ml streptomycin). HeLa-A2 cells were 
also grown in RPMI 1640 medium with the same supplements plus 800Pg/ml 
(powder weight) Geneticin G-418 sulphate, a selective antibiotic which maintains the 
HLA-A2 gene insertion. 
The cells were grown in vented flasks at 37°C in a 5% CO2 air humidified incubator. 
Adherent cells were passaged by washing with PBS and the addition of 5ml of 
0.25% trypsin/0.02% versene (0.02% EDTA, 0.1% phenol red/ PBS pH 7.4) at 37°C 
until the cells were released from the flask. Cells were pelleted at 250xg in a 
Beckman GPR centrifuge (GH3.7 rotor) at room temperature for 5 minutes and 
resuspended in fresh media. Cells were stored frozen under liquid nitrogen in a 
freezing mix (90% heat inactivated foetal calf serum, 10% DMSO). 
CTLs were maintained in Iscove's medium (5% human serum, 100U/ml IL-2) and 
restimulated every 3 weeks. CTLs (5x105) were stimulated with matched peripheral 
blood lymphocytes (2x106) and B cells (5x105) in 2m1 Iscove's medium (5% human 
serum, 100U/ml IL-2,5µg/ml pHA) and allowed to proliferate for one week, 
replacing with fresh media. 
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2.3 DNA Preparation and Cloning Techniques 
2.3.1 General Molecular Biology Techniques 
The preparation of plasmid and M13 DNA and the transformation of competent cells 
were undertaken as described in Sambrook et al., (1989) unless stated. Small-scale 
preparation of plasmid DNA was performed using the QlAprep Spin Plasmid kit 
according to the manufacturer's protocol. All restriction endonucleases and DNA 
modification enzymes were used in accordance with the manufacturer's instructions. 
DNA digests and PCR products were separated by agarose gel electrophoresis (2.3.3) 
and gel-purified prior to subsequent cloning steps using the Stratech Geneclean II kit 
following the recommended instructions. 
2.3.2 Phenol/Chloroform Extraction and precipitation of DNA/RNA 
The DNA/RNA to be extracted was made up to a minimum volume of 200µ1 with 
TE unless otherwise stated. To this 0.5 volumes of Tris-saturated phenol was added 
and mixed by vortexing followed by 0.5 volumes of chloroform and further mixing. 
The organic and aqueous layers were separated by microcentrifugation at 13000xg 
for 5 minutes and the upper aqueous layer removed to another eppendorf tube. The 
extraction process was repeated 3 times followed by DNA/RNA precipitation. 
The DNA solution to be precipitated was mixed with 0.1 volumes of 3M sodium 
acetate pH6.0 and 2 volumes of ice-cold absolute ethanol on dry ice for at least 15 
minutes. 
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The RNA solution to be precipitated was mixed with 0.1 volumes of 7M ammonium 
acetate and 2.5 volumes of ice-cold absolute ethanol on dry ice for at least 15 
minutes. 
The DNA/RNA pellet was recovered by centrifugation at 17,800xg in a Heraeus 
refrigerated microcentrifuge for 20 minutes and the pellet washed with 100µl 70% 
ethanol by centrifugation as above for 5 minutes. The pellet was dried in a vacuum 
desiccater and resuspended in TE or water. 
2.3.3 Preparation of Competent Cells 
A 5m1 overnight culture of E. coli was used to inoculate 50m1 LB medium and grown 
in a shaking-incubator at 37°C/250rpm until it had reached an OD600 0.6 (approx. 2 
hours). The culture was transferred to a pre-cooled 50ml centrifuge tube and the 
cells harvested by centrifugation at 1500xg in a Beckman GPR bench centrifuge 
(GH3.7 rotor) for 10 minutes at 4°C. The pellets were gently resuspended in 25m1 
calcium chloride (0.5M)/15% glycerol and incubated on ice for 30 minutes. Cells 
were harvested as before and the pellet resuspended in 5m1 calcium chloride 
(0.5M)/15% glycerol. The cells were left for a minimum of one hour at 4°C before 
use in transformation (and for a maximum of 24 hours before being frozen at -70°C). 
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2.3.4 Separation of DNA fragments by Agarose Gel Electrophoresis 
0.8% w/v agarose/0.5xTBE gels containing 0.05% (w/v) ethidium bromide were 
used for the separation and isolation of DNA fragments (Sambrook et al., 1989). 
Gels were cast in a horizontal electrophoresis tank and a 40-8OmA current applied. 
DNA migration was visualised by short-wave ultra-violet illumination and 
photographed by a UVP (TMW-200) transilluminator (Upland, USA), gel- 
documentation system. 
2.3.5 Oligonucleotide Site-Directed Mutagenesis 
Single-stranded M13 wtSLT DNA was mutated using an oligonucleotide-directed 
Sculptor T7-polymerase mutagenesis kit (Amersham) according to the 
manufacturer's instructions. The active site mutant E167D SLT was prepared using 
the phosphorylated oligonucleotide 5' ACA GCT GAT GCT TTA CG 3'. Mutated 
single-stranded M13 DNA was transformed into competent 71-18 cells. Potential 
mutants were screened using a Hind1II digest. The mutation of GAA to GAT 
destroys a unique HindIH site in the SLT sequence. Mutants linearise whereas non- 
mutated DNA releases a -. 580bp fragment. 
2.3.6 DNA sequencing 
Single stranded M13 DNA and denatured plasmid DNA was sequenced using a 
SequenaseTM T7 DNA Polymerase kit version 2.0 (United States Biochemical). The 
kit was used in accordance with the manufacturer's instructions. Typically 1µg of 
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single stranded M13 DNA or 2µg of plasmid DNA was sequenced per reaction. 
Single stranded M13 DNA was obtained by the small-scale PEG precipitation 
method of DNA preparation (Sambrook et al., 1989). Plasmid DNA was prepared 
using the QlAprep spin miniprep kit (2.3.1) or large-scale plasmid DNA prepared 
using the alkaline lysis method (Sambrook et al., 1989). Plasmid DNA prepared 
using the alkaline lysis method was further purified for sequencing by mixing the 
DNA with glassmilk using the Stratech Geneclean II kit, following the recommended 
instructions for DNA purification. Plasmid DNA was denatured by diluting into a 
90µl volume of water and the addition of l0µ1 of 1OM sodium hydroxide for 5 
minutes at room temperature. The denatured DNA was precipitated by the addition 
of l0µ1 of 5M ammonium acetate and 250µ1 ice-cold ethanol, centrifuged for 15 
minutes at 4°C, washed with 70% ethanol and recentrifuged for 5 minutes at 4°C. 
Sequencing was carried out referring to the manufacturer's protocol and the samples 
run on polyacrylamide sequencing gels (2.2.6). 
2.3.7 Sequencing Gels 
6% w/v polyacrylamide/urea gels were used for the separation of sequencing 
products. The gel mix (24g of urea dissolved in 16.75m1 of water, 5m1 of lOx TBE, 
7.5m1 of 40% acrylamide/2% N, N'-methylene bis-acrylamide) was polymerized by 
the addition of 250µl of 10% ammonium persulphate and 29µl of TEMED and 
poured into 38cm x 15cm taped gel plates. The gels were pre-warmed and the 
sequencing samples electrophoresed at 40W for 1-3 hours. The gels were then dried 
and exposed to Fuji RX X-ray film overnight. Films were developed under 
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darkroom conditions with LX24 developer (1: 4 dilution), washed and fixed with 
Unifix (1: 4 dilution). 
2.3.8 Polymerase Chain Reaction (PCR). 
Specific mutagenic PCR conditions are described in Results (sections 3.3 and 
6.2/6.3). All reactions were carried out using a Hybaid thermocycler with a typical 
100µl reaction mix consisting of 84µl of water, lOµ1 of lOx PWO buffer, 2µl of 
stock dNTP's (each at l OmM), 1µl sense primer (1 mg/ml), 1µl antisense primer 
(lmg/ml), plasmid DNA (between 1 and 5 ng/pl), 0.5µl of PWO polymerase. PCR 
products were purified by gel isolation (2.3.1) prior to further enzyme reactions. 
2.4 Expression of Recombinant Proteins in E. coli. 
2.4.1 Expression of wild-type SLT-1 holotoxin and SLT fusion proteins 
Recombinant SLT fusions were expressed in Escherichia coli and purified by 
globotriose-Sepharose affinity chromatography. A 10ml culture of E. coli TG2 
harbouring pUC19 plasmid containing SLT gene was grown overnight at 37°C, then 
used to inoculate 11 of LB media and grown to an optical density of 0.6 (2-3 hours). 
Expression of SLT was induced by the addition of 1mM isopropyl 1-thio-ß-D- 
galactoside (IPTG) to the culture and incubated for 3 hours at 37°C. Cells were 
harvested by centrifugation at 700xg for 30 minutes at 4°C and the periplasmic 
extract collected by osmotic-lysis of the cells. Cell pellets were resuspended in 20m1 
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tris/sucrose buffer (20% sucrose (w/v), 300mM Tris-HC1 pH8.0,1mM 
ethylenediaminetetra-acetic acid disodium salt (EDTA), 0.5mM magnesium 
chloride) and left at room temperature for 10 minutes. Cells were pelleted at 4400xg 
for 5 minutes at 4°C and resuspended in 10ml 1mM ice-cold Tris-HCI pH7.5. Cells 
were incubated on ice for 10 minutes then recentrifuged at 17500xg for 15minutes at 
4°C. The supernatant periplasm was filter-sterilized and applied to a 1ml 
globotriose-Sepharose affinity column (refer to 2.5.1). 
2.4.2 Expression of Ricin A-chain and RTA fusion proteins 
The expression of recombinant RTA was carried out exactly as described by Day et 
al., (1996). 
2.5 Protein Purification 
2.5.1 Purification of SLT-1 by Affinity Chromatography 
Recombinant holotoxins were purified to homogeneity from E. coli by receptor- 
ligand based chromatography using globotriose (a-D-galactose-(1--> 4)-ß-D- 
galactose-(1-> 4)-ß-D-glucose-(i-> )) coupled to a Sepharose matrix. The 
supernatant containing the E. coli periplasmic extract (2.4.1) was applied to a iml 
globotriose-Sepharose affinity chromatography column equilibrated in PBS. The 
column was washed with 500ml PBS and the SLT-1 eluted with 6M guanidine 
hydrochloride and collected in iml fractions. The absorbance of each fraction was 
determined at 280nm in a spectrophotometer and the fractions containing protein 
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were immediately dialysed against PBS, with buffer changes after 6 hours and 
overnight. The concentration of SLT-1 was determined by spectrophotometry (refer 
to 2.5.4). 
2.5.2 Purification of Ricin A-chain by Ion-Exchange Chromatography 
Recombinant RTA was purified as described in Day et al., (1996). In addition to the 
conditions described, various buffers and matrices were used to optimise the 
purification of RTA fusion proteins, described in Results (section7.5). 
2.5.3 Reassociation of Ricin A-chain with Ricin B-chain 
Typically 50µg of ricin A-chain was mixed with 50µg of ricin B-chain (Inland Labs) 
or ricin B-chain made from native ricin holotoxin (refer to 2.5.4)in a total volume of 
200µl in PBS, by gentle agitation on a tumbler at 4°C for 4 hours. Reassociated 
holotoxin was then purified from free A-chain by applying to a 0.5m1 a-lactose 
(insolubilized on 6% beaded agarose) column equilibrated with PBS. The holotoxin 
was loaded onto the column in a final volume of lml in PBS and passed through the 
column a total of 4 times. The column was washed with 5m1 PBS and the holotoxin 
(and free B-chain) eluted with 4m1 of 50mM galactose collecting 0.5m1 fractions. 
2.5.4 Preparation of free ricin B-chain 
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Ricin holotoxin (20mg) in 10mM Tris ph8,5% ß-mercaptoethanol, 0.1M lactose in a 
total volume of 50m1 was stirred overnight at 4°C. The reduced ricin was then 
loaded onto a 75m1 DEAF Sephacel (Pharmacia) column equilibrated in buffer 
(10mM Tris pH8,1% ß-mercaptoethanol, O. 1M lactose). Free A-chain was washed 
from the column with 250m1 of the same buffer, collecting the wash in 10ml 
fractions. Ricin B-chain was eluted with a linear 500m1 0.1-0.3 M sodium chloride 
gradient and the fractions collected analysed by reducing SDS-PAGE. 
2.5.5 Determination of Protein Concentration 
The concentration of recombinant SLT 1 holotoxins (with the exception of SLT- 
CMa) and ricin A-chains was determined by measurement at 280nm using a 
Shimadzu UV 160A spectrophotometer. Optical density values at 280nm were 
converted to protein concentrations from a extinction co-efficient calculated from the 
formula:. 
E A280nm = 12.075x[No. Tyr + (5x No. Trp)] / Total No. amino acids. 
SLT 1 holotoxin extinction co-efficient = 0.984 
Ricin A-chain extinction co-efficient = 0.77 
For this formula, the protein concentration calculated from C A280nm has been 
converted to mg/ml. 
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The concentration of SLT-CMa was determined by scanning densitometry 
comparisons of the SLT A-chain of known wtSLT holotoxin concentrations (in 
triplicate), against SLT-CMa after reducing SDS-PAGE and silver staining of 
samples (refer to 2.5.6). The concentration of this fusion protein was calculated in 
this way due to the presence of excess B-chain on gels. Assuming the stoichiometry 
of 1A: 5B chains is always correct, the concentration of A-chain is directly 
proportional to the concentration of holotoxin present as holotoxin is purified by the 
ability of SLT B-chain to bind to globotriose-Sepharose. 
Ricin holotoxins, generated by the association of free RTA with free RTB, were 
quantified in a similar manner to SLTC-Ma, by ricin A-chain densitometry 
comparisons of known concentrations of recombinant ricin A-chain. This step is 
necessary to take account of unassociated ricin B-chain. Reducing SDS-PAGE gels 
were either silver-stained or coomassie stained and the A-chains quantified on a 
Molecular Dynamics Computing Densitometer. The concentration of A-chain is 
directly proportional to the concentration of holotoxin present, as the a-lactose 
column is washed free of unbound ricin A-chain before the reassociated ricin is 
eluted. 
2.5.6 Storage of Recombinant proteins 
Recombinant SLT-1 holotoxins and fusion proteins were stored for short periods of 
time (up to 2 months) in PBS at 4°C or long-term in PBS at -70°C. Recombinant 
ricin A-chain and fusion proteins were stored long-term at 4°C. Ricin holotoxin and 
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fusion proteins were routinely stored at 4°C but can be stored at -20°C (in 15% 
glycerol). 
2.5.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE). 
Proteins were routinely separated on 15% polyacrylamide gels described in 
Sambrook et al., (1989) in reducing or non-reducing conditions where, in the latter, 
ß-mercaptoethanol was omitted from the sample-loading buffer. 
Gels were visualised by silver-staining (Merrel et al., 1981) or by Coomassie 
Brilliant Blue R250 staining (Sambrook et al., 1989). 
2.5.8 Western Blot Analysis 
Protein samples were electrophoresed by SDS-PAGE (2.5.6), then transferred onto a 
Hybond-C nitrocellulose filter (Amersham) in transfer buffer (25mM Tris, 192 mM 
glycine, 20% methanol) using a Sigma-Aldrich techware semi-dry blotting system. 
The blotting apparatus was run at a constant voltage (150V) for 1 hour. The filter 
was removed to a clean box and blocked with TBS (10mM Tris pH8.0,150mM 
sodium chloride) containing 0.1% Tween-20 and 5% dried skimmed milk (TBS-T- 
M) for 30 minutes with shaking at room temperature. The TBS-T-M was replaced 
with 40m1 of fresh TBS-T-M containing the primary antibody at an appropriate 
dilution and incubated for 1-4 hours at room temperature. The filter was washed 3 
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times for 5 minutes with 100ml of TBS-T-M and the secondary antibody conjugated 
to alkaline phosphatase added to the filter in 20m1 of TBS-T-M for 1 hour at room 
temperature. The filter was washed with TBS-T as before with an additional 3 
washes with TBS. The filter was developed by the addition of 33µl of nitroblue 
tetrazolium (NBT) and 66µl of 5-bromo-l-chloro-3-indolyl phosphate (BCIP) 
(Promega) in 10ml of alkaline phosphatase buffer (100mM Tris-HC1 pH 9.5,100mM 
sodium chloride, 5mM magnesium chloride) until staining was complete and the 
reaction stopped by the addition of 10mM Tris, pH8.0,5mM EDTA. The filter was 
dried at room temperature. 
2.6 In vitro Ribosome Inactivation assay 
All solutions used in the preparation or treatment of ribosomes and RNA were kept 
as RNase-free as possible. Equipment (polycarbonate tubes, glass rods, gel tanks) 
was soaked in O. 1M sodium hydroxide overnight and rinsed with distilled water. 
Polycarbonate tubes and glass rods were baked before use. 
2.6.1 Preparation of Rabbit Reticulocyte Ribosomes 
lml of non-nuclease-treated rabbit reticulocyte lysate (Promega) was carefully 
layered on lml of an ice-cold 1M sucrose pad in lx ENDO buffer (25 mM Tris, 
pH7.6,25mM potassium chloride, 5mM magnesium chloride) in a 3m1 TL-100 
thick-walled polycarbonate tube. This was centrifuged at 412,000 xg (100 000 rpm) 
in a Beckman TL-100 ultracentrifuge (using a TL-100 rotor) for 45 minutes at 4°C. 
The supernatant was carefully removed allowing the sucrose pad to be poured away 
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and the ribosome pellet gently washed twice with lml of ice cold 1xENDO by 
adding the 1xENDO and immediately pouring off. The pellet was gently 
resuspended in lml 1xENDO with a glass rod and recentrifuged as before. The 
pellet was washed with 1xENDO as previously and resuspended in l00µ1 final 
volume ensuring the glass rod is washed free of ribosomes. The concentration of 
ribosomes was calculated by measuring the optical density of a diluted sample at 
280nm using the formula that 1mg/ml of ribosomes is equivalent to 12.5 OD26onm 
units. Ribosomes were stored in aliquots at -70°C. 
2.6.2 Nicking of SLT-1 furin-sensitive site prior to incubation with ribosomes. 
Before SLT-1 was incubated with ribosomes, the furin-sensitive site located between 
SLTA1 and A2 was cleaved with trypsin to release the catalytic Al subunit from A2. 
Various trypsin concentrations and incubation times were tested with SLT-1 (see 
results) to ensure 100% cleavage of the site, visualized on reducing SDS-PAGE by a 
single A-chain band the size of Al (26KDa). 
Sequencing grade trypsin (Boehringer Mannheim) was added at 0.5µg/ml in PBS to 
2µg of SLT-1 in a final volume of lOµ1 then incubated for 1 hour at 37°C. The 
reaction was stopped by the addition of 1 tl of 10mg/ml PMSF in isopropanol and 
the nicked SLT-1 stored at 4°C until required. 
2.6.3 Toxin incubation with ribosomes, extraction and aniline-cleavage of 
depurinated RNA. 
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Endo and Tsurugi (1988) first described the N-glycosidase activity of SLT-1 and 
ricin to remove a specific adenine residue from a highly conserved stem-loop region 
of yeast and mammalian RNA which can be visualized by aniline treatment and the 
subsequent cleavage of a fragment of rRNA. This method was modified by May et 
al. (1989). 
A range of nicked SLT-1 (2.6.2) and ricin dilutions were mixed with 30µg of rabbit 
reticulocyte ribosomes (2.6.1) in lx ENDO buffer to a fmal volume of 20gl (6mM ß- 
mercaptoethanol was added to the SLT-1 samples to reduce the disulphide bridge 
and release the catalytic Al subunit) then incubated for 30 minutes at 30°C. 
Reactions were stopped by the addition of 180µl of 1% SDS. The samples were then 
phenol/chloroform extracted 3 times before RNA precipitation with ice-cold, 0.1 
volumes of 7M ammonium acetate and 2 volumes of absolute ethanol on dry-ice for 
15 minutes (2.2.1). The RNA was pelleted, washed by the addition of 70% ethanol, 
dried under vacuum and resuspended in 20gl of water. 
The concentration of RNA was determined by measuring the optical density at 
260nm of a diluted sample of each reaction (1.0 OD260 = 40pg/ml of rRNA). To 3 
µg of modified RNA, 20µ1 of 1M acetic aniline, pH4.5 was added and incubated for 
2 minutes at 60°C followed by the addition of 0.1 volumes of ammonium sulphate 
and 2 volumes of absolute ethanol. The rRNA samples were precipitated as before 
and the dried pellets resuspended in 20µ1 of 60% deionized formamide in O. lx TPE 
(3.6mM Tris, 3mM sodium dihydrogen phosphate dihydrate, O. 1mM EDTA, pH8). 
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Non-aniline treated rRNA controls containing 3µg rRNA were diluted to 20gl with 
60% deioninzed formamide/O. lx TPE. The samples were incubated at 65°C for 5 
minutes before the addition of 4p1 of RNA sample buffer (50% glycerol, O. 1xTPE, 
0.05% bromophenol blue). The rRNA samples were resolved on denaturing 
formamide-agarose gels (2.6.4). 
The N-glycosidase activity of the toxins was quantified by measuring the densities of 
the resolved 28S rRNA reticulocyte ribosomes and 390-ribonucleotide fragment, 
released upon treatment with aniline. RNA was visualised under U. V., photographed 
with Polaroid black and white and the negative quantified by a Molecular Dynamics 
Computing Densitometer. Alternatively northern blot analysis of the RNA was 
carried out (Methods, 2.6.6), for quantification by a Molecular Dynamics 
Phosphorimager. The percentage depurination (toxin activity) of the reticulocyte 
ribosomes was determined by dividing the density of the aniline fragment by the 
combined densities of the aniline fragment plus the 28S rRNA and multiplying by 
100. 
2.6.4 Extraction of RNA from SLT-1 treated HeLa cells 
Typically, 1.5 ml of HeLa cells were plated in flat bottomed 6-well plates at 2.5x105 
cells/ml and treated overnight with various concentrations of SLT-1. The cells were 
washed 3 times with PBS and then dissolved in 0.5m1 denaturing buffer (6M 
guanidine hydrochloride, 20mM MES [4-morpholineethan-sulfonic acid] pH7.0, 
20mM EDTA, 50mM ß-mercaptoethanol [added just before use]) by incubating at 
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room temperature for 5 minutes. The cell suspension was then removed to an 
eppendorf tube and extracted twice with phenol/chloroform (2.2.1) and precipitated 
with 0.1 volumes of 7M ammonium acetate and 2.5 volumes of absolute ethanol on 
dry ice for 30 minutes. The RNA was pelleted by centrifugation at 8000xg for 15 
minutes at 4°C, washed with 70% ethanol and dried. The pellet was resuspended in 
lx DNase buffer (50mM Tris-HC1 pH7.5,1mM magnesium chloride) to a final 
volume of 100µ1 and 15 units RNase-free DNase (Gibco BRL) added for 30 minutes 
on ice. The RNA was phenol/chloroform extracted and precipitated as before and 
resuspended in lOµ1 sterile distilled water. 
2.6.5 Separation of RNA by Formamide-Agarose Gel Electrophoresis 
The rRNA samples were loaded onto horizontal denaturing formamide gels (1.2% 
RNase-free agarose, 50% deionized formamide, O. 1xTPE) and electrophoresed, 
without submerging, in O. lx TPE at 24mA until the sample buffer had run half-way 
across the gel. The gel was stained in 500m1 water containing 50µl of 10mg/ml 
ethidium bromide, shaking for 30 minutes at room temperature, before destaining in 
water for at least 15 minutes. The RNA was visualised under UV and photographed 
with Polaroid black and white, positive/negative film. 
2.6.6 Northern blot analysis 
Northern blot analysis was used to visualize the 400 ribonucleotide RNA species 
produced by cleavage of modified rRNA upon aniline treatment by probing with an 
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oligonucleotide complementary to the 3' region of rabbit reticulocyte 28S rRNA 
(with the base sequence 5'CAT AAT CCC ACA GAT GG 3'). 
Following separation of rRNA on denaturing formamide gels (2.6.5), the gel was 
then washed in 500m1 of 50mM sodium hydroxide for 20 minutes followed by 
500ml of 20xSSC (3M sodium chloride, 0.3M tri-sodium citrate pH7) for 45 
minutes. The rRNA was then transferred from the gel onto a nitro-cellulose 
membrane (Hybond-N, Amersham), pre-soaked in 20x SSC, using a vacuum blotting 
system (Vacugene, Pharmacia) referring to the manufacturer's instructions. The 
rRNA was transferred for 1 hour after which the membrane was rinsed in 6xSSC and 
air dried. The transferred rRNA was cross-linked to the membrane using a 
Stratagene UV Stratalinker. 
The oligonucleotide was labelled by phosphorylation using T4 DNA kinase. In a 
final volume of 20gl, 50pmol of oligonucleotide was incubated with 20gCi of [32 P]- 
y-ATP in 1x kinase reaction buffer (70mM Tris pH 7.6,10mM magnesium chloride, 
5mM DTT) with 1µl of T4 polynucleotide kinase (Gibco BRL) at 37°C for 45 
minutes, then at 70°C for 10 minutes. The phosphorylated oligonucleotide was 
precipitated with 1Oµ1 of 3mg/ml sonicated salmon sperm DNA (Pharmacia), 0.1 
volumes of 7M ammonium acetate and 2.5 volumes absolute ethanol for 30 minutes 
on dry ice, then pelleted by centrifugation at 8000g for 30 minutes. The pellet was 
washed in 70% ethanol and allowed to air dry. The dried pellet was resuspended in 
3O0µ1 water and used immediately for hybridization. 
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The membrane cross-linked with rRNA was soaked in hybridisation buffer (6xSSC, 
0.3% SDS, 5x Denhardt's reagent [made as a 50x stock: 10mg/ml Ficoll 400, 
10mg/ml polyvinylpyrrolidone, 10mg/ml BSA]) before being pre-hybridized by 
incubation with 10ml of hybridisation buffer containing 30µl of 3mg/ml heat- 
denatured sonicated salmon sperm DNA for 2 hours at 37°C in a hybridisation bottle 
placed in a rotating oven (Hybaid). The buffer was then discarded and 10ml of fresh 
hybridisation buffer containing the phosphorylated oligonucleotide (passed through a 
DynaGard filter) was added and incubated overnight at 37°C. The buffer containing 
oligonucleotide was discarded and the membrane washed with 100m1 of 2xSSC for 
30 minutes at 37°C in the oven. The membrane was wrapped in Clingfilm and 
placed in a phosphorimager cassette for quantification by a Molecular Dynamics 
Phosphorimager or exposed to RX X-ray film with an intensifying screen overnight 
at -70°C. 
2.7 Cytotoxicity Assay 
Cytotoxicity comparison of wt and D167SLT-peptide chimeras against HeLa A2.1 
cells and wtSLT against SK-mel-29. Cell were plated in flat bottomed 96-well 
plates (1.5* 104 cells per well) and left to adhere overnight at 37°C. The cells were 
then washed with PBS and the toxin dilutions added in RPMI (5% FCS) in a total 
volume of 150µl per well. Cells were then incubated for 16hrs at 37°C. Cells were 
washed with PBS and labelled with 35S-Methionine (lpCi (3000Ci/mmol) per well) 
for 2 hours. Labelled proteins were then precipitated by washing the cells 3 times 
with 5% trichloroacetic acid and washing the cells once with PBS. Protein synthesis 
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was measured by the incorporation of 35S-Methionine in cells and a percentage 
calculated in relation to toxin-free control cells from 4 replicate dilution samples. 
2.8 51Cr-release Cytotoxic -T- lymphocyte Assay 
HeLa A2 cells were challenged with D167SLT-Ma chimeras (20ng/ml) overnight. 
The cells were then washed and 51Cr- labelled (50gCi/million cells) for 1hr at 37°C. 
Cells were then plated with CTLs at 5: 1 and 2: 1 effector/target ratios and incubated 
for 4 hrs at 37°C before 51Cr-release counting. HeLa-A2 cells were treated with y- 
interferon (100U/ml) for 48 hrs before challenging with toxin. Control HeLa-A2 
cells were infected with 5 plaque forming units (pfu)/cell of vaccinia-encoded 
influenza Matrix (Ml) for 90 minutes and allowed to express influenza Matrix 
protein overnight prior to 51Cr-labelling or infected with the vaccinia at the same 
time as 51Cr-labelling. If the latter was the case, cells were incubated with M1 
vaccinia and 51Chromium (50gCi/million cells) for 90 minutes at 37°C, washed and 
incubated for a further 3 hours at 37°C to allow expression of influenza Matrix 
protein Cells were treated with lactacystin (100µM in water) for 1 hr and then 
incubated overnight at a final concentration of 1µM lactacystin in RPMI medium. 
The lactacystin was washed off the cells with the toxin prior to 51Cr-labelling. 
Influenza matrix peptide (0.1µM) was plated with control 51Cr-labelled HeLa A2.1 
cells and CTLs. 
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Chapter 3 
The construction of expression plasmids for E167D SLT 
and SLT-Ma fusions proteins. 
3.1 Introduction 
In order that target cells were not destroyed in the process of peptide delivery, an 
active site mutant of SLT-1 (glutamate 167 to aspartate; E167D) was prepared by 
oligonucleotide-directed T7 polymerase mutagenesis. The activity of E167D SLT-1, 
purified to homogeneity from E. coli by receptor-ligand based chromatography, was 
assessed by in vitro ribosome-inactivation assays and in vivo cytotoxicity 
comparisons with wild-type SLT-1 (see Chapter 4). 
The ability of SLT-1 to deliver antigenic peptides to class-1 MHC molecules was 
tested by placing a peptide at the C-terminus and N-terminus of the SLT A-chain. 
The possible advantage of placing the peptide at the C-terminus of the A-chain was 
that it left the restricted anchor residue at the C-terminus of the epitope free access to 
the class-1 MHC groove after B-chain dissociation in the ER lumen. A possible 
disadvantage of placing the peptide at the C-terminus of the SLT A-chain is that it is 
not known whether the A2 fragment of the chain is translocated into the cytosol. If 
this is the case, the epitope would not be available for cytosolic processing by 
proteasomes. The association between the C-terminus of SLT A-chain and the B 
pentamer may also make the epitope inaccessible for processing within the ER. By 
contrast, the N-terminus of the SLT A-chain is sterically unhindered by the presence 
of the B-chain. 
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Influenza matrix peptide 58-66 (Ma, GILGFVFTL-single letter code) was chosen as 
the epitope for the SLT fusion since an HLA-A2.1 stably transfected HeLa cell-line 
was available to us along with Matrix 58-66-specific CTL. In particular, influenza 
Matrix peptide consists predominantly of hydrophobic amino-acyl residues and may 
be more stable when placed at the C-terminus of the SLT A-chain compared to a 
charged epitope such as influenza Nucleoprotein 366-374 (ASNENMDAM). This is 
due to the position of the C-terminal end of the SLT A-chain when associated with 
the B-chain pentamer. The C-terminus of the A subunit, consisting of a helical 
segment of hydrophobic residues penetrates the pore formed by the B-chain 
pentameric ring (Fraser et al., 1994). Thus a hydrophobic peptide placed at the C- 
terminus of the SLT A-chain may be better tolerated. 
Approximately 2000A of the A subunit is buried by the B pentamer (Fraser et 
a1., 1994), a result of the contact between the C-terminal helix and the B subunits. 
The positioning of a peptide at the end of the A-chain may therefore potentially 
disrupt the non-covalent association between the A-chain and B pentamer. 
To ensure that the presence of the peptide did not interfere with normal trafficking of 
the toxin moiety, M58-66 was also conjugated to the wild type toxin. 
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3.2 Construction of plasmid E167D SLT 
M13 wtSLT DNA was mutated using a Sculptor T7-polymerase mutagenesis kit (see 
Methods, 2.2.4). This protocol is summarised in Figure 3.1. The mutated M13 
DNA was then cut with the restriction enzymes EcoRl and Pstl consecutively to 
release a 1.3 Kb fragment containing the entire bicistronic operon. This was ligated 
into the SLT expression vector PUC19 that had been digested similarly and 
dephosphorylated with calf alkaline intestine phosphatase (CIP). The entire SLT 
insert was sequenced using 8 sequencing primers spanning the SLT sequence and 
forward/reverse vector primers. 
3.3 Construction of SLT-Ma expression plasmids. 
DNA coding for the influenza Matrix peptide 58-66 (GILGFVFTL) was genetically 
fused with the 5'- or 3'-terminus of DNA encoding the catalytic A-chain of SLT by 
mutagenic PCR. The was performed by a two-step PCR strategy. The first step is 
the amplification of two DNA products in separate reactions. Two primers were 
designed, one that contains a sequence complementary to the sense genomic 
sequence and the other a non-complementary sequence, both primers also encoding 
for the Ma peptide. The two DNA products (one lKbp and the other 300bp) are 
complementary in the region encoding Ma. In the second step of the PCR, the two 
DNA products are annealed together and end-filled by PWO polymerase alone. The 
annealed DNA is then amplified by the addition of M13 PCR primers resulting in a 
1.5Kbp PCR product which can be digested and ligated back into the expression 
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Figure 3.1 Construction of pE167DSLT 
SculptorTM in vitro mutagenesis system 
Mutant Oligonucleotide 
ACA GCT GAT GCT TTA CG 
EcoRl Pstl 
WTSLT recombinant ssDNA template 
Extension with dCTPaS 
& ligation 
Removal of ssDNA template 
Annealing 
ACA GCT GAT GCT TTA CG 
EcoRl Pstl 
Digestion of nicked 
non-mutant strand 
with T5 exonuclease 
Repolymerisation 
using DNA 
Nicking non-mutant strand 
with Nci I. 
EcoRl Pstl 
Transformation 
E167D SLT 
Cut EcoRl/Pstland ligate into PUC19 
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vector. The PCR strategies for SLT-Ma construction are detailed in Figure 3.2 and 
Figure 3.3. The PCR conditions are shown below in table 3.1. 
Hot start denaturing Annealing Extension 
94°C 94°C Variable 72°C 
SLTC-Ma 30s 1 min 1 min 
reaction 1 63°C 
SLTC-Ma 30 s 
1 min 1 min Reaction 2 63°C 
1 min 30s 
5C 1 min SLTC-Ma 4 
Reaction 3 (add primers) 30 s 
I min 1 '/: min 55 C 
SLTN-Ma 30s 1 min 1 min Reaction 1 65°C 
SLTN-Ma 30s 1 min 1 min Reaction 2 65°C 
1 min 30s 
4 äC 1 min SLTN-Ma 5 
Reaction 3 (add primers) 30 s 
S C 1i min S 
* all reactions were concluded with a7 min incubation at 72°C to allow full extension. 
Table 3.1 PCR conditions for the construction of pSLTC-Ma and pSLTN-Ma. 
PCR reactions were typically carried out in a total volume of 50µl or l00µ1 (see 
Methods, 2.2.7) using a Hybaid thermocycler. The products of reactions 1 and 2 
(amplified by 30 cycles of PCR) were gel purified (see section 2.3.1) and 
approximately 1 ng of each DNA used in reaction 3. Reaction 3 consisted of 10 
cycles of PCR in the presence of PWO (O. 51i1) alone followed by the addition of 
M13 vector primers and extra PWO (0.5µ1) for 30 cycles. 
The product of reaction 3 was digested with Pstl and EcoRl and ligated into PUC19 
(see Methods, 2.3.1). 
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Figure 3.2 Construction of SLT N-Ma by 2-stage mutagenic PCR 
Stage 1 
Reaction 1 Ma sense sequence complementary to SLT-A chain (N terminus) 
11 
5' GGC ATC TTG GGC TTC GTC TTT ACA CTG AAG GAA TTT ACC TTA GAC TTC 
Primer 
SLTA-NMa N-Ma 
SLT 
SLT operon 
Reaction 2 
Ma anti-sense sequence 
0. 
14 M13 Universal primer 
complementary to SLT signal sequence 
11 
I 
5' CAG TGT AAA GAC GAA GCC CAA GAT GCC CGC CAC CAC ATT AAC TGA AAA G 3' 
Primer 
SLTSS-NMa M13 Reverse primer 
, SLT operon 
ý SLT N-Ma 
Reaction 3 
Anneal and end-fill 
Reaction 1 product 
(=1.3Kb) / 
Reaction 2 product 
(114bp) 
Add DNA polymerase 
Reaction 4 
M13 Amplification 
Reverse 
1 primer Pst I Ma 
(=1.4Kb) 
Cut with Pstl/EcoRl 
ligate into PUC19. 
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i EcoR lM 13 
Universal 
primer 
Figure 3.3 Construction of SLT C-Ma by 2-stage mutagenic PCR 
Stage 1 
Reaction 1 Ma sense sequence complementary to SLT-B chain (N terminus) 
11 
5' GGC ATC TTG GGC TTC GTC TTT ACA CTG TGA GGG GGT AAA ATG AAA AAA 3' 
10 
Primer 
SLTB-Ma C-Ma 
SLT operon 
Reaction 
5 
Ma anti-sense sequence 
f- 
M13 Universal primer 
complementary to SLT-A chain (C terminus) 
1 11 1 
TCA CAG TGT AAA GAC GAA GCC CAA GAT GCC ACT GCT AAT AGT TCT GCG CAT 3 
Primer 
SLTA-Ma M13 Reverse primer 
º SLT operon 
SLT 
Stage 2 
Reaction 3 
Anneal and end-fill 
Reaction 1 product 
(300bp) 00000 
Reaction 2 product 
(%w1.1Kb) 
Add DNA polymerase 
Reaction 4 
M13 Amplification 
Reverse 
Pst I primer Ma 
(m1.4Kb) 
Cut with Pstl/EcoRl 
Ligate into PUC19. 
EcoRl M13 
Universal 
primer 
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CHAPTER 4 
THE ACTIVITY ASSESSMENT OF E167D SLT-1 AND 
CONSTRUCTION OF SLT-1 FUSION PROTEINS 
Chapter 4 
The activity assessment of E167D SLT-1 and construction of 
SLT-1 fusion proteins. 
4.1 Introduction 
The SLT constructs made were all expressed from the vector pUC19 where 
expression can be driven by the lac Z promoter. The pUC19 expression plasmids 
contain the full length bicistronic operon for SLT, encoding both the SLT A-chain 
and B-chain and its associated Shine-Dalgarno and periplasmic targeting sequences. 
The recombinant protein is targeted to the periplasmic space as this allows the 
association of A and B chains and disulphide bond formation in a compartment 
analogous to that in naturally producing strains of E coll. 
All manipulations involving pUC19 SLT in the wild-type background must be 
carried out under category III biological containment conditions as the plasmid 
contains a holotoxin gene under the control of a strong promoter that constitutively 
expresses the gene at low levels. 
Reassociated SLT was purified by its affinity for globotriose ceramide, the 
carbohydrate moiety of the SLT-binding receptor. Globotriose ceramide was 
chemically synthesised and coupled to Sepharose by the laboratory of Professor 
David Crout (Warwick). This matrix has a high affmity for SLT, binding wild-type 
holotoxin at approximately lmg/ml of matrix. 
81 
The activity of E167D SLT, purified to homogeneity from E. coli by receptor-ligand 
based chromatography, was assessed by in vitro ribosome-inactivation assays and in 
vivo cytotoxicity comparisons with wild-type SLT. This mutant SLT was previously 
reported to cause a 1000-fold reduction in activity as measured by the ability of 
crude SLT-containing E. coli periplasmic extracts to inhibit protein synthesis by 
rabbit reticulocyte lysate (Hovde et al., 1988). 
4.2 Preparation of E167DSLT 
E167D SLT was expressed and purified as for wtSLT (refer to Methods, 2.4.1 and 
2.5.1). The substitution of glutamate 167 to aspartate had no affect on the level of 
expression of SLT in TG2 E. coli cells and E167D SLT was directed to the periplasm 
in a soluble form in the same way as wtSLT. E167DSLT was purified to 
homogeneity by receptor-ligand based chromatography using globotriose coupled to 
a Sepharose matrix and visualised on 15% reducing- SDS-PAGE gels (Fig 4.1). The 
concentration of SLT was calculated by optical density measurement at 280nm and 
using the extinction coefficient, c=0.984 (Methods, 2.5.4). 
4.3 Nicking of SLT-1 furin-sensitive site to release catalytic Al subunit. 
Before activity comparisons between E167DSLT and wtSLT could be made by 
direct assays on mammalian ribosomes in vitro, the catalytic Al subunit had to be 
released from A2 which partially blocks the active site and therefore reduces N- 
glycosidase activity. In the standard protocol of this laboratory, SLT is nicked with 
O. lµg/ml sequencing grade trypsin (Boehringer Mannheim) for 7 minutes. Early 
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kDa 
31.0 ýý... ý-. 
A chain (32kDa) 
16.4gý 
8. B chain (7.6kDa) 
MT FTI FT2 E1 E2 
Figure 4.1 Expression and purification of El 6 7D SL T 
E167D SLT was expressed in IPTG induced Escherichia coli TG2 cells 
harbouring pUC19 containing the SLT1 bicistronic operon for 3 hours. 
Cells were harvested and osmotically lysed to release assembled 
E167DSLT oligomers. The resulting high speed supernatant was filter 
sterilized and applied to a lml globotriose-Sepharose affinity column 
equilibrated in PBS. E167DSLT was subsequently eluted with 6M 
guanidine hydrochloride, dialysed against PBS and selected samples 
analysed by reducing 15% SDS-PAGE gels. T refers to a sample of total 
E. coli extract, FT refers to a sample of column flow through, E refers to 
eluted E167DSLT fractions; SLT A and B chains are labelled (M, 
molecular weight markers). 
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ribosome-inactivation assays indicated a degree of discrepancy between the activity 
of different batches of E167D SLT and wtSLT. After separating the trypsin-treated 
SLT by SDS-PAGE on 15% reducing gels it was found that the A-chain was only 
partially nicked resulting in the loss of the A2 subunit (26kDa). This varies between 
different batches of SLT as processing of the furin sensitive site occurs naturally 
when SLT is stored at 4°C over a period of time, of which E167DSLT appears to be 
more susceptible. To ensure complete digestion of the furin-sensitive site, SLT was 
incubated with various concentrations of sequencing-grade trypsin (Boehringer 
Mannheim) and analytical grade trypsin (Sigma) at different time intervals (Fig 4.2). 
The digested samples were separated by reducing SDS-PAGE on 15% gels and 
silver-stained. Complete cleavage of the furin-sensitive site is visualised by the loss 
of the full size SLT A-chain (32kDa) and the appearance of the SLT Al fragment. 
Figure 4.2 shows that digestion is complete after a1 hour incubation with 5gg/ml 
trypsin. If the concentration of trypsin used or the incubation time is reduced, a full 
size A-chain band can still be visualised on a reducing gel by silver-staining. 
4.4 In Vitro ribosome inactivation assays 
The ID50 of wtSLT is the concentration of toxin which depurinates 50% of 
ribosomes. The ID50 of wtSLT is typically 100pg/pl, when incubated with rabbit 
reticulocyte ribosomes (20-30µg) for 30 minutes at 30°C. No depurination of rabbit 
reticulocyte ribosomes was visualised on aniline gels for E167DSLT over a range of 
toxin concentration 25ng/µ1-0.5ng/µl, over the same range an aniline fragment is 
seen with wtSLT. In order to make a comparison with wtSLT and the catalytic 
mutant the toxin range was increased to 75/µl-5ngtpl and the incubation period 
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untreated 
wtSLT 
ýý 
I* 
0.5 µg/ml 1 µg/ml 5 µg/ml 
trypsin trypsin trypsin 
( 
kDa 
"7 A 
ý ýýýý 
26 Al 
7 30 60 7 30 60 7 30 60 (mins) 
40.. wa .ý 
Figure 4.2 Digestion of wtSLTat 37°C, over various time intervals and 
concentrations of trypsin 
ýB 
wtSLT samples (1µg) in 20µl of PBS were incubated at 37°C for 7 minutes, 30 
minutes or 1 hour with various concentrations of sequencing grade trypsin 
(Boehringer Mannheim). The reaction was stopped by the addition of I µl of 
10mg/ml PMSF in isopropanol. The samples were separated on 15% reducing 
SDS-PAGE gels and silver-stained. SLT A, Al and B chains are labelled. 
Complete cleavage of the site is visualised by the loss of the full size SLT A- 
chain. Digestion is complete after a1 hour incubation with 5gg/ml Trypsin. 
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increased to 45 minutes or 1 hour. After 1 hour at 30°C the reticulocyte ribosomes 
were found to be degraded so a 45-minute incubation period was used to calculate 
the decrease in activity of E167DSLT compared to wtSLT. Ribosomes were treated 
with 25ng/pl-25pg/gl of wtSLT and 50ng/µl-50pg/pl of D167SLT in a total volume 
of 2Oµ1. The rRNA samples were resolved on a denaturing formamide-agarose gel 
(Methods, 2.6.4). The aniline fragments generated were visualised by northern blot 
analysis (Fig 4.3). The aniline fragments were then quantified by image-quant and 
percentage depurination calculated for the samples (Fig 4.4). The ID50 of E167D 
SLT was calculated to be I0000pg/pl, a 100 fold decrease in in vitro ribosome 
depurination activity compared to wtSLT. 
4.5 Cytotoxicity comparisons of E167D SLT with wtSLT 
HeLa-A2 cells were plated into 96-well tissue culture plates and allowed to adhere 
overnight at 37°C. This was followed by the addition of dilutions of toxin, further 
incubation and the labelling of cells with 35 S-Methionine (described in Methods, 
2.7). The typical IC50 of wtSLT (the concentration of toxin at which protein 
synthesis is 50% that of untreated cells), tested on standard HeLa cells is 0.01 ng/ml 
and for ricin is 0. ing/ml. When tested on the stably transfected HLA-A2 HeLa cell 
line the IC50 was found to be the same for wtSLT but the cells were less susceptible 
to ricin having an IC50 of 5 ng/ml after overnight incubation with ricin compared to 
an IC50 of 0.4ng/ml for standard HeLa cells in the assay of figure 4.5. These HeLa 
may be of a different subtype or have altered galactosylation owing to the 
transfection of HLA-A2 DNA. The IC50 of E167D SLT was calculated to be 
IOOng/ml compared to 0.1ng/ml for wtSLT (for the assay shown in figure 4.6), 
representing a 1000 fold loss in in vivo activity. 
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WTSLT E167DSLT ricin 
A-chain 
r--~ý 
(ng/µ1) 25 25 5 0.5 0.05 0.025 50 25 5 0.5 0.05 10 
miw«* 
404*4049 
Aniline 
Fragment 
10 woýmwarr 
w 
Fig. 4.3 Northern blot analysis of ribosome depurination activity of 
E167D SLT and wtSLT. 
Rabbit reticulocyte ribosomes (were incubated for 45 minutes with various 
concentrations of wtSLT and E167DSLT (given in ng/µg) and 
subsequently treated with acetic-aniline as described in methods. The 
rRNA samples (2.5µg of each) were resolved on a denaturing formamide- 
agarose gel and northern blot analysis was used to visualize the 400 
ribonucleotide species ('Aniline Fragment') produced by the cleavage of 
modified rRNA. The aniline fragments were quantified by Image-quantTM 
and a percentage depurination calculated (Fig4.4). NA refers to rRNA 
from sample 1 (25ng/pl wtSLT) not treated with acetic-aniline. 
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Fig 4.4 Quantification of the depurination of rabbit reticulocyte ribosomes by 
wtSLT and E167D SLT. 
Comparison of the percentage depurination of rabbit reticulocyte ribosomes 
byWTSLT (o ) and E167DSLT (" ). Depurination values were determined by 
the optical density measurements, using Image Quant, of aniline fragments and 
28S ribosomes from Fig 4.3 (see Methods, 2.6.3 for calculation). 
The ID50 values, the concentration of toxin where 50% of ribosomes are 
depurinated, were calculated as: WTSLT=100pg/µl E167DSLT=10000pg/µl 
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Fig 4.5 Cytotoxicity of ricin on HeLa cells and HLA-A2 transformed HeLa cells 
Cells were incubated with various concentrations of ricin for 6 hours at 37°C 
before [35S]-Methionine labelling and protein precipitation with 5% TCA. Protein 
synthesis was measured by the incorporation of [35S]-Met into protein and a 
percentage calculated in relation to toxin-free cells. HeLa cells ", HLA-A2 
transformed HeLa cells 0. 
T-T-iTTTl T -T-TTTIFq 
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Figure 4.6 Cytotoxicity of E167D SLT compared to wtSLT 
Cytotoxicity of wtSLT( o) and E167 DSLT (") towards HeLa-A2 cells. 
Cells were incubated with various concentrations of SLT proteins, in 
quadruplicate, for 16 hours at 37°C before adding [35S]-Methionine (lµCi/well) 
and incubating for a further 2 hours. Cell proteins were precipitated by washing 
with 5% trichloroacetic acid and radioactivity measured by liquid scintillation 
counting. Protein synthesis was measured by the incorporation of [35S]- 
Methionine into protein and a percentage calculated in relation to toxin-free 
control cells. Values shown are the means of quadruplicate determinations and 
the error bars represent one standard deviation from the mean. 
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4.6 Extraction of E167DSLT treated HeLa ribosomes 
To confirm that E167D SLT is able to be endocytosed by HeLa-A2 cells, given its 
low level of cytotoxicity, ribosomes were isolated from toxin treated HeLa-A2 cells 
using a guanidine hydrochloride method that instantly denatures SLT during cell 
lysis. Ribosomes were examined for SLT-specific modification by performing 
aniline assays (Fig4.7). 
4.7 Expression of SLT-Ma fusion proteins 
The Ma peptide fusion proteins, in both native and E167DSLT backgrounds, were 
expressed and purified using a protocol as for wtSLT (Methods, 2.2) (Figure4.8). 
The presence of the influenza matrix peptide in both fusions decreased the level of 
expression 2-3 fold. Expression at 30°C, which lowers the rate of protein folding 
and often increases the level of expression, did not alter the amount of SLT-Ma 
produced suggesting the problem may be one of protein stability. Expression in 
minimal medium was also tried in an attempt to permit a short burst of SLT fusion 
production. Low levels of lactose are present in rich LB medium resulting in 
premature induction of transcription from the lacZ promoter and early production of 
SLT. The use of minimal medium means that SLT is only expressed when 
transcription is switched on by the deliberate introduction of the gratuitous inducer 
IPTG once the cells have reached an optical density of 0.6 at 600nm. This strict 
control of SLT-Ma expression did not alter the amount of Ma fusion proteins 
produced. 
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Figure 4.7 Denaturing gel analysis of aniline treated rRNA from intoxicated 
HeLa-A2 cells. 
HeLa-A2 cells were incubated with 0.05ng/ml wtSLT (1), 100ng. ml E167D 
SLT (2) or without toxin (3) at 37°C overnight. In all cases cells were dissolved 
in 6M guanidine hydrochloride, 20mM Mes pH7,20mM EDTA, 50mM 3- 
mercaptoethanol for 5 minutes at room temperature and the RNA precipitated, 
treated with DNase and reprecipitated as described in methods. Extracted RNA 
was subjected to acetic-aniline treatment as previously described and the rRNA 
resolved on denaturing formamide-agarose gels. 
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Figure 4.8 SDS-PAGE of purified SLT-Ma fusion proteins 
SLTB 
A)Recombinant SLT fusions were expressed on IPTG induction of Escherichia 
coli TG2 cells harbouring pUC19 containing the SLTI bicistronic operon for 3 
hours. Cells were harvested and osmotically lysed to release assembled E167D 
SLT oligomers. The resulting high speed supernatant was filter sterilized and 
applied to a Iml globotriose-Sepharose affinity column equilibrated in PBS. 
SLT-Ma was subsequently eluted with 6M guanidine hydrochloride, dialysed 
against PBS and selected samples analysed by reducing 15% SDS-PAGE. T 
refers to a sample of total E. coli extract, FT refers to a sample of column flow 
through, E refers to eluted E 167DSLT fractions; SLT A, Al and B chains are 
labelled. B) Reducing SDS-PAGE to compare the apparent molecular weights 
of SLT N-Ma and SLT C-Ma A-chains with native SLT A-chain. 
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4.8 Cytotoxicity of SLT-Ma fusion proteins 
To ensure that the presence of the peptide did not interfere with normal trafficking of 
the toxin moiety, M58-66 was genetically fused to the wild type toxin and its activity 
compared to that of naked wtSLT (Figure 4.9). The wtSLT fusions were as potent as 
wtSLT with an IC50 value of O. Oing/ml. The peptide chimeras engineered using 
E167D SLT were, as expected, approximately 1000 fold less toxic. 
4.9 Mass Spectrometry of SLT-Ma fusion proteins 
To confirm the entirety of the influenza Matrix peptide within the SLT-Ma fusion 
proteins, the toxin chimeras were analysed by electrospray ionization (ESI) mass 
spectrometry (Fisons VG Quattro-II). The samples were dialysed from PBS into 
2mM ammonium bicarbonate and their mass determined. The predicted molecular 
mass of SLT A and B chain is 32199.47 and 7688.66 Da respectively The predicted 
molecular mass of the peptide containing A chains is 33148.58 Da. The presence of 
the full influenza Matrix nonamer in both constructs was confirmed with molecular 
masses of 33148.47 +/- 0.31 and 33148.08 +/- 2.83 Da for SLT N-Ma and C-Ma 
respectively when the fusion proteins were purified in the presence of a protease 
inhibitor cocktail (Boehringer Mannheim). Degradation products were observed 
when toxin was purified in the absence of protease inhibitors with a value of 
32543.27 +/- 0.06. for SLT C-Ma and 32117.86 +/-1.07 for SLT N-Ma. This loss in 
mass could not be accounted for and did not represent residues lost from the Ma 
peptide. 
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Figure 4.9 Cytotoxicity of wild-type and E167D SLT-Ma chimeras to HeLa-A2cells 
Cytotoxicity comparison of wild-type and E167D SLT-Ma chimeras against HeLa-A2 
cells. Toxins are represented by: wtSLT N-Ma ( ), wtSLT C-Ma (0), 
E167DSLT N-Ma (") and E167DSLT C-Ma (o). Cells were incubated with 
various concentrations of SLT proteins, in quadruplicate, for 16 hours at 37°C before 
pulse labelling with [35S]-Methionine, cell lysis and scintillation counting (as 
described in Methods). Protein synthesis was measured by the incorporation of [35S]- 
Met into protein and a percentage calculated in relation to toxin-free control cells. 
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CHAPTER 5 
THE DELIVERY OF INFLUENZA MATRIX PEPTIDE 
INTO THE MHC CLASS 1 PATHWAY BY E167D SLT 
Chapter 5 
The delivery of influenza matrix peptide into the MHC class 1 pathway by 
E167D SLT. 
5.1 Introduction 
The in vitro ability of the engineered SLT fusion proteins to deliver influenza matrix 
peptide to MHC class 1 molecules was tested by pulsing HeLa-A2 target cells with 
toxin and then mixing with Matrix 58-66-matched CTL. Sensitisation to lysis by the 
SLT fusion proteins was quantified by loading the target cells with radioactive 
S'Chromium and measuring its release in sensitised cells. The expression of HLA- 
A2 MHC class 1 molecules by the stably transfected HeLa cells was confirmed by 
FACS analysis. Appropriate controls were carried out to demonstrate that the HeLa- 
A2 cells were capable of processing and presenting intracellular antigens. To 
confirm that intracellular proteases rather than serum proteases generated the M56- 
66 epitope, a cell-line resistant to SLT was used as alternative target cells. 
The mode of transport and processing of the SLT fusion proteins were also studied 
by pre-treating HeLa-A2 cells with brefeldin-A or lactacystin, before challenging 
with the toxin constructs. The cellular affects of these agents are described in the 
Introduction (sections 1.3.2.4 and 1.6.1). HeLa cells were found to be deficient in 
processing epitopes for presentation and the MHC class-1 processing machinery was 
enhanced by pre-treatment of HeLa cells with interferon-y. Over 200 genes are 
presently known to be upregulated by IFN-y, some of these have direct effects on the 
MHC class 1 processing pathway (detailed in Introduction, section 1.6.6). Others 
may generally increase the overall trafficking in cells, potentially having an affect on 
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the cytotoxicity of toxins taking advantage of a retrograde transport pathway from 
endosomes via the trans-Golgi network to the ER. 
5.2 HeLa-A2 transfected cells express HLA-A2 MHC class 1 molecules. 
To confirm that the HeLa cells transfected with HLA-A2 DNA were expressing A2 
MHC class-1 molecules, FACS analysis was carried out on the cells. An A2- 
positive B cell-line and standard HeLa cells were used as positive and negative 
controls respectively. Cells were stained with an HLA-A2 mouse monoclonal 
antibody and a FAB-specific FITC secondary antibody. A muscle-specific primary 
antibody was used as a control for non-specific staining and secondary antibody-only 
stains also carried out (Figure 5.1). FACS analysis confirmed that the HeLa-A2 cells 
were expressing HLA-A2 class 1 molecules and showed a 10-fold increase in 
fluorescence compared to standard HeLa cells. 
5.3 Ability of SLT fusion proteins to deliver exogenous antigen into the MHC 
class 1 presentation pathway. 
To demonstrate that HeLa-A2 cells were capable of processing and presenting 
intracellular antigens, two positive controls were performed. HeLa-A2 cells were 
infected with vaccinia virus encoding full length influenza Matrix protein at the same 
time as 5'Cr-labelling of the cells. In other assays HeLa-A2s were mixed with free 
Ma peptide (2µM) when plated out with CTLs. 
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Figure 5.1 Flow cytometry analysis of HLA-A2 transfected HeLa cells 
Cells were stained with either an HLA-A2 specific (BB7.2) or a muscle specific 
mouse monoclonal antibody for 1 hour before staining with a goat anti-mouse FAB- 
specific FITC-conjugated secondary antibody for 1 hour. Cells were fixed in 1% 
paraformaldehyde before FACS analysis. A) Muscle-specific antibody stain of 
HeLa-A2 (- )and non-transfected (---- ) HeLa cells. BS FITC- conjugated 
secondary only antibody stain of HeLA-A2 cells (- ) and an A2-positive B cells 
line (- -. ). C) HeLa-A2 (- ), HeLa (-- ) and A2-positive B cells (- - -) stained 
with an HLA-A2 specific antibody. D) Comparison of HeLa-A2 cells stained with 
non-specific primary (" ""') and secondary only (......... ) controls with those stained 
with BB7.2 (-) 
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When HeLa-A2 cells are challenged overnight with E167D SLT, protein synthesis 
starts to decrease at 5-10ng/ml toxin. At lOng/ml on average, protein synthesis 
occurs at 70% that of untreated control cells. This concentration was taken as the 
maximum amount of toxin that could be used to treat the cells overnight before cells 
started to decrease in numbers and couldn't be used in subsequent CTL assays. 
HeLa-A2 cells were challenged with a range of SLTN-Ma and SLTC-Ma 
concentrations (ing/ml-lOng/ml) and incubated at 37°C overnight. Cells were 
washed free of surface bound toxins by washing twice in PBS (lOmis) and used in 
CTL lysis assays (Methods, 2.8). CTL-specific lysis was calculated as a percentage 
of cell lysis resulting from 51Cr-loaded HeLa-A2 cells mixed with CTLs and HeLa- 
A2 cells mixed with 5% triton (100% cell lysis). Background 51Cr-release was taken 
into account by subtracting the cell lysis from 51Cr-loaded HeLa-A2 cells incubated 
in PBS. No CTL-specific lysis was observed after the addition of SLTN-Ma and 
SLTC-Ma up to an overnight incubation concentration of lOng/ml. Over several 
independent experiments, the typical cell lysis observed for cells infected with 
VacMl or mixed with exogenous Ma was between 5-10% (Fig. 5.2). CTL-specific 
lysis increased when HeLa-A2 cells were infected with VacMl the day prior to use 
in CTL assays and allowed to express influenza Matrix protein overnight. 
To enhance CTL-specific lysis, HeLa-A2 cells were treated with interferon-y 
(100units/ml) for 48 hours prior to toxin incubation and use in CTL assays. The 
toxin concentration applied to cells was also increased to 20ng/ml as incubation of 
HeLa-A2 cells overnight with lOng/ml E167DSLT-Ma fusions had not diminished 
the number of live cells required to carry out the CTL assays. 
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Figure 5.2 Lysis of chromium-labelled HeLa-A2 cells by Matrix 58-66 specific 
CTL 
51 Cr-loaded HeLa-A2 and . 45 B cells were treated with M1 vaccinia virus, 
Matrix 58-66 peptide or PBS and plated with CTLs at effector/target ratios of 5: 1 
(white bars) and 2: 1 (black bars). Cells were then incubated for 4 hours at 37°C 
before 51Cr-release counting (Methods, section 2.8). This represents 1 of 5 
equivalent sets of data. 
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Specific cell lysis of interferon-y treated HeLa-A2 cells was enhanced 3-6 fold in 
cells expressing full length influenza Matrix protein and 2-fold in interferon-y treated 
HeLa-A2 cells where exogenous Ma peptide was applied. Significantly, specific 
CTL lysis of interferon-y treated HeLa-A2 cells was observed when target cells had 
been treated with SLTN-Ma. In contrast, no cell lysis was observed when SLTC-Ma 
was applied to HeLa-A2 cells, even though the SLT fusion could be internalised by 
HeLa-A2 cells (refer to Figure 4.9). Results of 7 independent experiments revealed 
similar effects, one typical set of results is shown in Figure 5.3. Statistical analysis 
comparing IFN-y-treated HeLa-A2 cells and untreated cells, incubated with SLTN- 
Ma revealed a significant difference in cell lysis, with aP value of < 0.0001 
(calculated using a paired t-test). These results were consistent with a IFN-y- 
dependent upregulation of the class 1 processing and presentation pathway. 
5.4 The effect of interferon-y treatment on HeLa-A2 cells 
Expression of the MHC-encoded proteasomal subunits, LMP2 and LMP7, was 
significantly enhanced after incubation of HeLa cells with IFN-y as shown by 
western blotting using anti-LMP2 and anti-LMP7 mouse monoclonal antibodies 
(Figure 5.4). FACS analysis of IFN-y treated HeLA-A2 cells also confirmed that 
MHC class 1 molecules are generally upregulated by IFN-y (Figure 5.5). 
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Figure 5.3 HeLa-A2 cells incubated with SLT N-Ma are sensitised for lysis by 
Matrix 58-66 specific CTL 
HeLa-A2 cells were incubated with E167DSLT-Ma chimeras (20ng/ml) overnight, 
washed and labelled with 51 Chromium. Cells were then plated with CTLs at 5: 1 
(black bars) and 2: 1 (white bars) effector: target ratios and incubated for 4 hours at 
37°C before 51 Cr-release counting. HeLa-A2 cells were treated with IFN- Y 
(100U/ml) for 48 hours before the incubation with toxin. HeLa-A2 cells were 
infected for 90 minutes with 5 plaque forming units (pfu)/cell of vaccinia virus 
encoding influenza Matrix (Ml). Cells were then washed and allowed to express 
influenza Matrix protein overnight prior to 51 Cr-labelling. 
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Figure 5.4 Western blot of interferon-y treated/untreated HeLa-A2 cells 
against LMP2 and LMP7proteasomal subunits 
HeLa-A2 cells were pre-treated with interferon-y for 48 hours. Total proteins 
were resolved by SDS-PAGE along with untreated HeLa-A2 cells and subjected 
to Western blot analysis. Bands were visualised by the use of LMP-2 and LMP-7 
specific antibodies and a HRP-conjugated secondary antibody. 
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Figure 5.5 Flow cytometry analysis of HeLa-A2 cells upregulated by 
interferon-r. 
HeLa-A2 cells were pre-treated with interferon-y for 48 hours before staining 
with HLA. A2 (A) or MHC class 1 (B) antibodies and a FITC-conjugated 
secondary antibody. Standard HeLa cells (HLA. A2 negative) were also 
stained. 
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5.5 Interferon-y treatment of HeLa-A2 cells increases their sensitivity to wtSLT 
HeLa-A2 cells were treated with IFN-y (100U/ml) for 48 hours before their 
sensitivity to wtSLTN-Ma was compared to that of untreated cells. WtSLTN-Ma 
cytotoxicity increased 3-fold in HeLa-A2 cells treated with IFN-y (Figure 5.6). This 
is likely to be due to a overall enhancement of trafficking in the cell, upregulated by 
Interferon-y . 
5.6 The M58-66 epitope must be internalised to sensitise target cells for lysis 
To confirm that the M58-66 epitope was generated by intracellular proteases rather 
than serum proteases, the melanoma line Skmel-29, which is naturally resistant to 
SLT (Figure 5.7) was used to provide target cells. The results of these experiments 
are shown in Figure 5.8. Skmel-29, whilst sensitised for lysis when free A2-MAGE- 
3 peptide 271-279 was applied, were not sensitised for lysis by the addition of 
SLTN-Ma (Figure 5.8a). 
In addition brefeldin-A blocked CTL specific lysis of HeLa-A2 treated with SLTN- 
Ma and HeLa-A2 cells infected with Ml vaccinia virus (Figure 5.8b). It is known 
that brefeldin-A treated cells are resistant to wtSLT as the toxin is unable to pass 
through the Golgi network. This was also shown to be the case for wtSLTN-Ma 
(Figure 5.7), implying that the presence of the peptide does not affect toxin routing. 
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Figure S. 6 Cytotoxicity of wtSLTN-Ma to interferon-ytreated HeLa-A2 cells 
HeLa-A2 cells were pre-treated with 100U/ml interferon-y for 48 hours before 
incubation with various concentrations of wtSLTN-Ma and pulse-labelling with 
[35S]-Met. Interferon-y treated cells (0) are shown compared to untreated cells (u) 
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Figure 5.7 Susceptibility of brefeldin-A treated HeLa-A2 cells (o)and 
untreated HeLa-A2 cells (0) to wtSLT- NMa. 
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Cells were incubated with 5µg/ml brefeldin A (BFA) or PBS for 1 hour prior to 
toxin addition. BFA was maintained throughout the assay at 2.5pg/ml. Cells 
were incubated with various wtSLTN-Ma concentrations for 16 hours at 37°C 
before pulse labelling with [35S]-Met as described in Methods. The melanoma 
line Skmel-29 (  ), which is naturally resistant to wt SLT is also shown. 
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Figure S. 8 The ability of SLT- resistant Skmel-29 cells to be sensitised for lysis and 
the effect of BFA and lactacystin on CM-specific lysis of SLTN-Ma treated HeLa- 
A2 cells. 
A) SKmel-29 cells were incubated with SLTN- Ma toxin under the same conditions 
as HeLa-A2 cells (Figure5.5). The ability of Skmel-29 cells to be sensitised for 
CTL-specific lysis was determined using the A2 MAGE-3 peptide 271-279 (10µM 
for 1 hour). Cells were incubated with Matrix 58-66 specific CTL or 271-279 
MAGE-3 specific CTL at effector/target ratios of 27: 1 (black bars) and 9: 1 (white 
bars). B) HeLa-A2 cells were treated with interferon-y and incubated with either 
SLT N-Ma or M1 vaccinia. Cells were incubated with BFA (5µg/ml) or PBS for 1 
hour before addition of SLT N-Ma or M1 vaccinia. BFA was maintained at this 
concentration throughout the assay. C) Cells were treated with lactacystin (100µM) 
for 1 hr and then incubated with SLT N-Ma overnight in a final concentration of 
11µM Lactacystin. The Lactacystin was washed off the cells with the toxin prior to 
5 Cr-labelling. 
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CHAPTER 6 
THE CONSTRUCTION OF EXPRESSION PLASMIDS 
FOR RTA ACTIVE-SITE MUTANTS AND 
RTA-PEPTIDE FUSION PROTEINS 
Chapter 6 
The construction of expression plasmids for RTA active-site mutants and RTA- 
peptide fusion proteins. 
6.1 Introduction 
Protein toxins such as ricin and SLT must first bind cell surface receptors in order to 
be endocytosed and exert their toxic effect on cells. Ricin binds to both glycolipids 
and glycoproteins with terminal galactose, thus a large number of toxin molecules (3 
x 107 molecules per HeLa cell) are able to bind the majority of cells. Shiga toxin and 
Shiga-like toxin-1 (SLT-1) bind to a limited number of receptors at the cell surface 
(106 receptors per cell in sensitive HeLa cells) and are only able to bind members of 
the globo-glycolipid family, primarily to globotriose (Gb3)-ceramides. In addition, 
these receptors are found in only certain tissue types, such as kidney endothelial 
cells, although the affinity of Shiga-toxin and SLT for these cell types is very high. 
An advantage of creating ricin fusion proteins is the potential to deliver peptide to all 
cells, including professional antigen presenting cells, such as dendritic cells. 
Previous studies have shown that the active-site mutant E177D ricin A-chain (RTA) 
which is functionally equivalent to that of E167D SLT reduces catalytic activity 80- 
fold when assessed by an assay based on protein synthesis inhibition (Schlossman et 
al., 1989). More recent studies have shown that the active-site mutant R180H-RTA 
reduces the cytotoxicity of R180H- ricin applied to Vero cells by 1000-fold (Day et 
al., 1996). 
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Ideally, a peptide delivery system should be non-toxic. This can be achieved using 
SLT by fusing peptides to the SLT B-chain and expressing the B-chain chimera 
alone (Lee et al., 1998) but this is impossible with ricin as the B-chain is unstable 
when expressed without ricin A-chain. 
The catalytic mutations E177D and R180H of RTA were combined in an attempt to 
produce a catalytically inactive mutant ricin. Influenza Matrix peptide 58-66 (Ma) 
and influenza Nucleoprotein 366-374 (NP) were placed at the N-terminus of RTA. 
NP was also placed within an external loop (residue 113-114), accessible by a CIaI 
site. 
6.2 Construction of active-site RTA expression plasmids. 
Mutagenic PCR was performed on the RTA expression plasmid, pUTA (Ready et 
al., 1991). Separated primers were designed containing the base changes for E177D 
and R180H on separate primers. The entire pUTA plasmid was amplified using 
these primers by inverse PCR (i PCR). Details of these PCR reactions are shown in 
Figure 6.1. The plasmid was amplified by 30 cycles of PCR (94°C for 30 s, 55°C for 
1 min and 72°C for 31/2 min) then a further extension period at 72°C for 7 minutes. 
Fragments were gel purified and phosphorylated by incubation with T4 
polynucleotide kinase (Gibco BRL), following the manufacturer's instructions. The 
plasmid was then ligated using T4 DNA ligase (Gibco BRL) and used to transform 
competent E. coli TG2 cells (Methods, 2.3.1). 
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Figure 6.1 Mutagenesis ofpUTA performed by inverse PCR 
A Insertion of El 77D or R180H mutations (shown in bold) within RTA 
Primer 
TCA GAA GCA GCA AGA TTC CAA TAT 
RTA sequence 
177 180 
Primer 
ý 
D177-RTA (primer IL) 5' TGC TGC ATC TGA AAT CAT TTG G 3' 
E177-RTA (primer 1) 5' TGC TGC TTC TGA AAT CAT TTG G 3' 
H180-RTA (primer 2) 5' CAT TTC CAA TAT ATTGAG GG 3' 
R180-RTA (primer 2) 5' AGA TTC CAA TAT ATT GAG GG 3' 
B Construction of RTAClal--NP chimera by inverse-PCR 
NP\, -º 
ClaI site 
i 
RTA sequence 
RT \ý 
RTA-NP1 5' T CTC GTT GCT CGC ATT TTG AAC ATC AGT GAA AAG 3' 
(antisense, letters in bold coding for the first 13 bases of the NP peptide) 
RTA-NP2 5' AT ATG GAC GCC ATG CGA TAT ACA TTC GCC TTT 3' 
(sense, letters in bold coding for the last 14 bases of the NP peptide) 
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6.3 Construction of ricin-Ma and ricin-NP expression plasmids. 
DNA coding for the influenza Matrix peptide 58-66 (GILGFVFTL) was genetically 
fused to the N-terminus of E177D R180H RTA by mutagenic PCR. A construct 
placing influenza Nucleoprotein 366-374 (ASNENMDAM) in the same position was 
also made. A similar PCR approach was used as for the construction of SLT-Ma 
plasmids. The PCR strategy is shown in Figure 6.2 and Figure 6.3. NP was also 
placed within a Cla I site (residue 113-114) by inverse PCR (Fig 6.1) such that the 
restriction-site was destroyed and could be used as a marker (by digesting potential 
candidates with ClaI) for incorporation of the NP sequence. Reaction conditions for 
the construction of these fusion proteins are given below (table 6.1). 
hot start denaturing annealing extension 
94°C 94°C variable 72°C 
RTAN-NP 1 min 
Reaction 1 30s 60°C 1 min 
RTAN-NP 1 min 
Reaction 2 30 s 60°C 1 min 
1 min 30s 
4 'C 1 min RTAN-NP 5 
Reaction 3 min (add primers) 30s 
5 
1 '/i min 5 
RTAN-Ma 30s 
1 min 1 min Reaction 1 65°C 
RTAN-Ma 30 s 
1 min 1 min Reaction 2 65°C 
min 1 min 30s 4 1 min RTAN-Ma 5 Reaction 3 F (add primers) 30s 5 C 1' min 5 
Table 6.1 PCR conditions for the construction of pRTAN-NP and pRTAN-Ma.. 
PCR reactions were typically carried out in a total volume of 50µ1 or 100µl (see 
Methods, 2.2.7) using a Hybaid thermocycler. The products of reactions 1 and 2 
(amplified by 30 cycles of PCR) were gel purified (see section 2.3.1) and 
approximately 1 ng of each DNA used in reaction 3. Reaction 3 consisted of 10 
cycles of PCR in the presence of PWO (O. 5µ1) alone followed by the addition of 
M13 vector primers and extra PWO (0.5µl) for 30 cycles. 
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Figure 6.2 Construction of RTAN-Ma by 2-stage mutagenic PCR 
Stage 1 
Reaction 1 Ma sense sequence complementary to RTA chain 
11 
5' GGC ATC TTG GGC TTC GTC TTT ACA CTG ATA TTC CCC AAA CAA TAC 3' 
Primer 
RTANMaU N-Ma ` 
RTA coding region 
Reaction 
Ma anti-sense sequence 
1 
Reaction 4 
5, CAG TGT AAA GAC GAA GCC CAA GAT GCC CAT AAG CTC GCC TCC TGA TC 
Primer 
pUC19 sense primer (609bp) TT A 1Th AT 
K1 H1V 1V1 äK -10 RTA coding region 
PUTA N-Ma 
Stage 2 
Reaction 3 
Reaction 1 product 
(=900bp) 
Reaction 2 product 
(= 200bp) 
Add DNA polymerase 
pUC 19 
sense 
primer Pst 
1 
M13 Universal 
complementary 
Ma 
(1.085Kb) 
Cut with BamHl/EcoRl 
1 
3' 
EcoR I M13 
Universal 
primer 
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Figure 6.3 Construction of RTAN-NP by 2-stage mutagenic PCR. 
Stage 1 
Reaction 1 NP sense sequence complementary to RTA chain 
1 11 
5' GCA AGT AAT GAA ATT ATG GAT GCA ATG ATA TTC CCC AAA CAA TAC 
Primer 
RTANNPU N-NP 
RTA coding region 
Reaction 
NP anti-sense sequence 
11 
CAT TGC ATC CAT ATT TTC ATT ACT TGC CAT AAG CTC CGC CTC CTG ATC 
5 
Primer 
pUC19 sense primer (609bp) TT " 1T 1TT 
K1 t-1lV IN t'lK -10 RTA coding region 
PUTA 
N-NP 
Stage 2 
Reaction 3 
Reaction 1 product 
(=900bp) 
111*1 
Reaction 2 product 
(= 200bp) 
Add DNA polymerase 
Reaction 4 
pUC 19 
sense 
primer 
ltl 
M13 Universal 
complementary 
Ma 
(1.085Kb) 
Cut with BamHl/EcoRl 
ý 3' 
3' 
EcoR1 M13 
Universal 
primer 
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CHAPTER 7 
THE ACTIVITY ASSESSMENT OF E177D R180H RICIN 
AND CONSTRUCTION OF RICIN FUSION PROTEINS. 
Chapter 7 
The activity assessment of E177D R180H ricin and construction 
of ricin fusion proteins. 
7.1 Introduction 
All the RTA constructs were expressed from the high-level RTA expression vector 
pUTA (Ready et al., 1991) which consists of the RTA coding sequence fused to a 
Shine-Dalgarno linker sequence and the lac Z promoter from plasmid pUC18. 
Hence expression can be driven by the lac Z promoter. Wild-type RTA is normally 
purified by cation exchange using carboxymethyl (CM)-Sepharose equilibrated in 
5mM sodium phosphate (pH6.5), since RTA is positively charged below its pI of 
pH7.5. The addition of a nonamer to RTA may potentially change the pI of the 
protein and alter the binding characteristics of the protein to CM-Sepharose. The 
peptide may carry a charge itself or affect the pI of RTA by preventing the correct 
folding of the protein. For this reason a range of buffers at various pHs were used to 
purify the RTA fusion proteins by cation and anion exchange chromatography. 
7.2 Preparation of E177D R180H ricin 
E177D R180H RTA was expressed in E. coli and purified on a CM-Sepharose 
column, equilibrated in 5mM sodium phosphate pH6.5. The loaded column was 
washed in 50-100m1 0.1M sodium chloride and E177D R180H RTA was eluted over 
a 0.1M-0.5M sodium chloride gradient in a total volume of 500m1. Mutant E177D 
R180H RTA peak fractions were typically collected between 160-210m1, a salt 
gradient range of 0.17-0.18M sodium chloride, eluting in the same pattern as wild- 
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type RTA (Figure 7.1). Typically less than 0.5 mg of RTA was obtained from a 
500m1 culture, approximately 30-fold less than wild-type RTA. As a test of 
solubility E177D R180H RTA was subjected to ultracentrifugation at 412,000 xg 
(100 000 rpm) in a Beckman TL-100 ultracentrifuge (using a TL-100 rotor) for 20 
minutes. The protein remained in the supernatant and was therefore deemed soluble, 
but after 3-4 weeks stored at 4°C the RTA had started to precipitate, indicating that 
the double mutant was more unstable than native RTA. 
7.3 In vitro ribosome inactivation assays 
The in vitro ribosome depurination activity of E177D R180H was assessed by 
aniline-cleavage assays (Methods, 2.6.3). Rabbit reticulocyte ribosomes were 
treated with RTA and mutant RTA from a range of 5 pg/µl to 375 ng/µl for 30 
minutes at 30°C. A typical formamide-agarose gel of the acetic-aniline treated 
rRNA samples is shown in Figure 7.2. Whilst an aniline fragment is clearly visible 
down to 25pg/µl (0.5ng total protein) wild-type RTA, an aniline fragment only 
appears at 25ng/µl (0.5µg total protein) E177D R180H RTA. From this 
visualisation, the catalytic activity of the double mutant can be estimated to be at 
least a 1000-fold down from wild-type RTA. 
7.4 Cytotoxicity comparison of E177D R180H ricin with native ricin 
E177D R180H RTA and wild-type RTA were reassociated with ricin B-chain as 
described in methods (section 2.5.3) and the concentration of ricin calculated by 
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Figure 7.1 Expression and purification of El 77D R180H RTA 
- 30.5 KDa 
An overnight culture of E. coli TG2 harbouring pUTA: E177D R180H plasmid 
was used to inoculate 500ml of 2TY media. Expression of RTA was induced by 
the addition of 0.05mM IPTG. Cells were harvested by centrifugation, 
resuspended in 5mM sodium phosphate (pH6.5) buffer and broken by sonication. 
Following centrifugation to remove cell debris, the supernatant was loaded onto a 
100ml carboxymethyl-Sepharose (Pharmacia) column equilibrated in the same 
buffer. Unbound protein was washed with 1500m1 5mM sodium phosphate 
(pH6.5) followed by a further 200m1 of buffer containing 100mM sodium 
chloride. E177D R180H RTA was eluted with a linear 500m1 0.1-0.3M sodium 
chloride gradient, collection of 10ml E177D R180H RTA fractions starting at 
; 0.17M sodium chloride. A high molecular weight protein was occasionally 
visualised in the RTA fractions which had no effect on the reassociation of RTA 
with ricin B-chain. Pre refers to a sample of pre-column sonicated E. coli 
supernatant , 
FT refers to a sample of column flow through, El 4-E 19 refers to 
eluted fractions of E177D R180H RTA (M, molecular weight markers). 
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E177D R180H RTA wt RTA 
ng/µ1 375 250 125 50 25 5 0.5 0.05 0.025 0.00 
Aniline 
Fragment 
No 
Figure 7.2 Northern blot analysis of ribosome depurination activity of 
E177D R180H RTA and wtRTA. 
Rabbit reticulocyte ribosomes (20µg) were incubated for 30 minutes with 
various concentrations of wtRTA and E177D R180H RTA (given in ng/µl) 
and subsequently treated with acetic-aniline (as described in Methods). The 
rRNA samples (2.5µg of each) were resolved on a denaturing formamide- 
agarose gel. 
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comparing the optical density of RTA bands separated by SDS-PAGE with known 
RTA concentrations. Cytotoxicity assays were carried out (Methods, 2.7) comparing 
E177D R18OH ricin with wild-type ricin. At 1OOng/ml E177D R18OH ricin, no 
activity was seen against HeLa cells compared to an IC50 of O. ing/ml calculated for 
wild-type ricin (Figure 7.3). 
7.5 Expression and purification of E177D R180H ricin fusion proteins 
Ricin-peptide chimeras were expressed using the same protocol as ricin. Influenza 
Matrix peptide (Ma) or influenza nucleoprotein (NP) was placed at the N-terminus of 
RTA. Influenza nucleoprotein (NP) was also placed within an external loop between 
residues 113-114 of the RTA chain. A range of pH buffers and ion-exchange 
matrices were used to purify these fusion proteins, detailed in table 7.1. RTAN-Ma 
was purified under identical conditions to wild-type RTA by applying to CM- 
Sepharose equilibrated in 5mM sodium phosphate pH6.5. When a sample of protein 
was centrifuged at 412,000 xg (100 000 rpm) for 20 minutes at 4°C using a TL100 
centrifuge and TL100 rotor (Beckman), RTAN-Ma was found to have precipitated, 
no protein was visualised in the supernatant when resolved by SDS-PAGE and 
analysed by Western blotting. RTAC1aI-NP bound to CM-Sepharose at a lower 
optimal pH (pH5.8) than wild-type RTA. This can be accounted for by the addition 
of a negatively charged nonamer. RTAN-NP was unable to bind CM-Sepharose 
over the pH range pH4-pH8. RTAN-NP bound to the anion-exchange matrix 
DEAE-Sephacel, along with the majority of E. coli proteins present in the expression 
extract which eluted in the same fractions as RTA. The RTA fractions collected 
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Figure 7.3 Cytotoxicity of wild-type and E177D R180H ricin to HeLa cells 
Cytotoxicity of ricin (") and E177D R180H ricin (o) towards HeLa cells. 
Cells were incubated with various concentrations of ricin proteins, in 
quadruplicate, for 16 hours at 37°C before adding [35S]-methionine (1tCi/well) 
and incubating for a further 2 hours. Cell proteins were precipitated by washing 
with 5% trichloroacetic acid and radioactivity measured by liquid scintillation 
counting. Protein synthesis was measured by the incorporation of [35S]- 
Methionine into protein and a percentage calculated in relation to toxin-free 
control cells. 
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were resolved by SDS-PAGE and visualised by Western blotting. There was no 
visible size difference between peptide-containing A-chains and native RTA. 
Peak RTA fractions were concentrated and reassociated with ricin B-chain 
(Methods, 2.5.3). In the case of RTAN-NP, unpurified extract was reassociated with 
RTB. 
Matrix CM-Sepharose CL-6B DEAE- 
Se hacel 
10mM 5mM 5mM 5mM 5mM 10mM 
Buffer (pH) acetic sodium sodium sodium sodium Tris 
acid phosphate phosphate phosphate phosphate 
pH4 H5.8 H6 pH6.5 pH8 H8 
RTAN-Ma X X " X 
RTAN-NP X X X X X " 
RTACIaI-NP " (optimal) " " 
Table 7.1 Purification conditions tested for E177D R180H RTA fusion proteins 
E. coli cells expressing RTA fusion proteins were harvested and resuspended in 30m1 
of the appropriate buffer and broken by sonication. Following centrifugation to 
remove cell debris, the supernatant was loaded onto a 100ml column equilibrated in 
the same buffer. Two types of matrix were tested, CM-Sepharose and DEAE- 
Sephacel. The carboymethyl (CM) group is a weak cation used in cation exchange 
for the recovery of positively-charged proteins. The diethylaminoethyl (DEAE) 
group is used in anion exchange to purify negatively charged proteins. X denotes 
where purification under the set conditions did not succeed and " denotes the 
conditions where protein bound and was successfully eluted from the matrix. 
7.6 Thermal denaturation of E177D R180H RTA 
As a measure of stability, E177D R180H RTA and wild-type ricin (1mg/ml) were 
incubated at 40°C for 5 minutes in a total volume of 50µl of O. 1M MES or O. 1M 
HEPES at a variety of pH values. Denatured protein samples were pelleted by 
centrifugation and 20µ1 aliquots analysed by SDS-PAGE on 15% gels and Western 
blotting. Figure 7.4 shows that E177D R180H remains soluble after a5 minute 
incubation at 40°C over a pH range 5.2-6.5. Wild-type RTA remains soluble at all 
the pH values tested. 
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Figure 7.4 Stability measurements of E177D R180H RTA compared to wt RTA. 
A) Thermal stability of E177D R180H RTA. RTA was incubated at 40°C for 5 
minutes at varying pH values in either MES or HEPES buffer. Denatured protein 
samples were pelleted by centrifugation and supernatant aliquots, resolved by SDS- 
PAGE on 15% gels. Remaining RTA was visualised by western blotting. 
B) Stability of E177D R180H RTA to proteolysis. The sensitivity of E177D R180H 
RTA to proteolysis was measured by incubating RTA with 1% trypsin (w/w) over a 
range of pH values. 
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A. Thermal stability of EI77D R180HRTA at 40°C. 
E177D H180 RTA 
MES HEPES 
pH 5.2 5.5 6 6.5 766.5 7 7.5 7.75 8 8.25 8.5 control 
. ýw 
wt RTA 
MES HEPES 
pH 5.2 5.5 6 6.5 766.5 7 7.5 7.75 8 8.25 8.5 
..... 
B. Stability of E177D R18OH to proteolysis. 
E177D H180 RTA 
MES HEPES 
pH 5.2 5.5 6 6.5 766.5 7 7.5 7.75 8 8.25 8.5 control 
4ý 
wt RTA 
MES HEPES 
1 
pH 5.2 5.5 6 6.5 766.5 7 7.5 7.75 8 8.25 8.5 
ý. ýý ý 
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7.7 Tryptic digestion of E177D R180H RTA 
E177D R180H RTA or wild-type RTA (1mg/ml) was incubated with 1% (w/w) 
trypsin in 0.1M HEPES or MES at various pH values at 37°C. After a 20 minute 
incubation period, the samples were boiled for 3 minutes with sample buffer and 
separated by SDS-PAGE (Figure 7.4). E177D R180H RTA shows increasing 
sensitivity to trypsin as the pH is increased and is only intact over the pH range 5.2- 
7.5. Under the same conditions RTA is visualised at all pH values. It must be noted 
that the activity of trypsin varies over the pH range tested (Spomer and Wooton, 
1971) thus the remaining RTA in different pH buffers can not be directly compared. 
The thermal and proteolytic stability data show that E177D R180H RTA is much 
less stable compared to wild-type RTA. As would be expected, the double mutation 
causes far greater instability of RTA than either of the mutations separately (Day et 
al., 1996). 
7.8 Expression and purification of R180H ricin fusion proteins 
R180H RTA fusion proteins were expressed and purified as for E177D R180H 
RTACIaI-NP, placing NP peptide at the N-terminus of RTA or within the CIaI site 
of RTA. Typical yields were 2-4 mg per 500m1 culture of each RTA fusion protein 
and reassociation with ricin B-chain was more efficient than that of the E177D 
R180H ricin-NP chimeras. Whereas reassociated E177D R180H ricin-NP chimeras 
could only clearly be visualised by Western blotting, reassociated R180H ricin-NP 
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bands could be seen by coomassie or silver-stained, non-reducing SDS-PAGE 
(Figure 7.5). It was possible to estimate the amounts of reassociated ricin fusions by 
comparing silver stained proteins of reassociated ricin, affinity purified on 
immobilised lactose prior to reducing SDS-PAGE, with known amounts of native 
RTA. Using these estimates of toxin concentrations, the cytotoxicity of the RI 80H 
ricin-NP toxins was calculated to be between 100-500 fold less than that of wild-type 
ricin (Figure 7.5). Day et al., (1996) have reported a loss in activity of up to a 1000- 
fold with R1 80H ricin compared to wild-type ricin. 
7.9 Ability of ricin fusion proteins to deliver exogenous antigen into the MHC 
class 1 presentation pathway. 
R180H ricin-NP fusion proteins were incubated overnight with ricin-sensitive 
murine L cells (H2-Db haplotype) at 2.5ng/ml. L cells treated with the toxins were 
tested for sensitisation for lysis by Nucleoprotein 366-374-specific CTLs 
(Figure. 7.6). Infection of L cells with a vaccinia virus encoding influenza 
Nucleoprotein sensitises them for lysis by matched CTL albeit at a relatively low 
level of 20%. However no killing is observed with L cells treated with the ricin-NP 
chimeras indicating that in this assay, ricin at this low concentration, is unable to 
deliver sufficient NP epitope into the MHC class-1 presentation pathway. 
129 
R180H RI 80H 
kDa RTAN-NP ricin ricinN-NP 
64 
50 "". s . 40M 
36 
30 '%am 40ý 
16 "I%ft 
6 
. ýý ricin (;: z60kDa) 
RTB (32kDa) 
ý""ý RTA (30kDa) 
Figure 7.5 Reassociation of purified RTA-NP fusion with RTB. 
Typically 50µg of ricin A-chain (RTA) was mixed with 50µg of ricin B- 
chain (RTB)(Inland Labs) in a total volume of 200µl in PBS, by gentle 
agitation on a tumbler at 4°C for 4 hours. Reassociation of RTA with 
RTB was confirmed by non-reducing SDS-PAGE. The RI 80H ricinN-NP 
reassociation mixture above (compared with control reassociated native 
ricin) consists of reassociated ricin together with remaining RTA and 
RTB. Free RTA may then be removed by applying the sample to a 0.5m1 
a-lactose (insolubilized on 6% beaded agarose) column equilibrated with 
PBS. 
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Figure 7.6 Cytotoxicity comparison of wt ricin and R180H ricin-NP 
fusion proteins 
Cytotoxicity of ricin (0), R180H ricinN-NP (0 ) and R180H ricinClal-NP (0) 
towards L cells. Cells were incubated with various concentrations of ricin 
proteins, in quadruplicate, for 16 hours at 37°C before adding [35S]-Methionine 
(1pCi/well) and incubating for a further 2 hours. Cell proteins were 
precipitated by washing with 5% trichloroacetic acid and radioactivity 
measured by liquid scintillation counting. Protein synthesis was measured by 
the incorporation of [35S]-Methionine into protein and a percentage calculated 
in relation to toxin-free control cells. 
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Figure 7.7 s' Cr-release CTL assay to assess the ability of ricin-NP 
fusions to deliver peptide to 112-Db class-I molecules. 
L cells with an H2-Db haplotype were incubated overnight with 
H180 ricin-NP fusion proteins at 2.5ng/ml. The cells were then 
washed and labelled with 51 Chromium. Cells were then plated with 
CTLs at 20: 1 (black bars), 10: 1 (white bars), 5: 1 (dark grey) or 2.5: 1 
(light grey) effector: target ratios and incubated for 4 hours at 37°C 
before 51 Cr-release counting. L cells were infected for 90 minutes 
with 5 plaque forming units (pfu)/cell of' vaccinia virus encoding 
influenza Nucleoprotein (NP) at the same time as chromium 
labelling. Cells were then washed and allowed to express influenza 
Matrix protein for 3 hours prior to plating with CTLs. 
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Chapter 8 
Discussion 
8.1 Overview. 
These results describe how a disarmed SLT holotoxin, carrying a well defined 
peptide epitope for influenza virus Matrix protein at the N-terminus of SLT A-chain, 
can be used to deliver antigens for intracellular processing and presentation by MHC 
class-I molecules in cultured cells. 
Other toxins (diphtheria (DT), anthrax toxin and Pseudomonas exotoxin A (PE)) 
have been used to deliver peptide epitopes to class-I MHC molecules (Stenmark et 
al., 1991; Donelly et al.; 1993, Ballard et al.; 1996, Goletz et al.; 1997). DT and 
anthrax toxin lethal factor (LF) are known to translocate into the cytosol from 
acidified endosomes which is therefore the likely site of entry into the cytosol for the 
toxin-peptide chimeras. Presumably, these become processed cytosolically and the 
released peptides then delivered to MHC class-1 molecules via TAP transporters in 
the ER membrane. 
PE, like SLT A-chain, is believed to translocate from the ER but unlike SLT, has 
never been visualised there. When PE was used to deliver antigenic peptides, 
treatment of target cells with brefeldin A had no effect on antigen presentation, 
although a requirement for PE-peptide internalisation had been shown by fixing cells 
at 4°C, thus blocking endocytosis and preventing sensitisation of target cells for lysis 
by CTLs. (Donelly et al., 1993; Ulmer et al., 1994). BFA inhibits both the transport 
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of PE to the ER and the association and transport of processed peptides with nascent 
HLA class-1 molecules. The authors proposed that the processing of PE-peptide 
fusions and the loading of peptide onto MHC class-1 molecules occurred in 
endosomes and that recycling of these complexes to the cell surface resulted in 
MHC-peptide presentation. It is still unclear whether MHC class-1 molecules can 
recycle via endosomes. Work by Neefjes et al., (1990) suggests that only MHC 
class-II molecules recycle between endosomes and the cell surface. Using 
neuraminidase to cleave sialic acid from cell surface MHC class-I and class-II 
molecules, it was found that only MHC class-II molecules become resialated (an 
indication of recycling back to the trans Golgi network). Other results (Reid and 
Watts, 1990) using primaquine, a reagent known to slow the recycling of 
endocytosed receptors, suggest that both MHC class-I and class-II molecules recycle 
from the cell surface. However, whereas MHC class-II molecules load peptide well 
at low pH, the affinity for class-I molecules and peptide decreases 100 fold below 
pH7. It would therefore seem unlikely for MHC class-I molecules to load with 
peptide in acidic endosomes (pH6), which may suggest that in the PE fusion study 
by Ulmer et al., (1994), the BFA used was not disrupting the Golgi totally. 
The results from this study suggest that the processing and subsequent presentation 
of a peptide epitope delivered to class-I molecules by SLT involves the trafficking of 
the SLT-peptide chimeras to the ER of target cells. Treatment of HeLa-A2 cells 
with BFA successfully blocked the presentation of the M58-66 epitope by class-1 
molecules at the cell surface. 
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8.2 Characterisation of E167DSLT and E167DSLT-Ma chimeras. 
The activity of E167D SLT, purified to homogeneity from E. coli by receptor-ligand 
based chromatography, was assessed by in vitro ribosome-inactivation assays and in 
vivo cytotoxicity comparisons with wild-type SLT (Chapter 4). The ID50 value of a 
toxin is the concentration of toxin which depurinates 50% of ribosomes. The ID5o of 
wtSLT is 5Opg/µl, when incubated with rabbit reticulocyte ribosomes (20-30µg) for 
30 minutes at 30°C. Under the same conditions, the ID50 of E167D SLT was 
calculated to be 518Opg/µl, a 100 fold decrease in in vitro ribosome depurination 
activity compared to wtSLT. The IC50 value of a toxin is the concentration of toxin 
causing 50% inhibition of cellular protein synthesis under the assay conditions used. 
The IC50 of E167D SLT was calculated to be lOng/ml compared to O. Oing/ml for 
wtSLT when incubated overnight with HeLa-A2 cells. This represents a 1000 fold 
loss in activity. 
To ensure that the presence of the M58-66 peptide did not interfere with normal 
trafficking of the toxin moiety, the peptide was genetically fused to the wild type 
toxin and its activity compared to that of naked wtSLT. The modified holotoxins 
were designated SLTN-Ma or SLTC-Ma, depending whether M58-66 is located at 
the N- or C-terminus of the A-chain. The wtSLT fusions were as potent as wtSLT 
with an IC50 value of O. Oing/ml on HeLa-A2 cells. The peptide chimeras engineered 
using E167D SLT were, as expected, approximately 1000 fold less toxic. 
Furthermore, the toxicity of wtSLTN-Ma was completely blocked when HeLa-A2 
cells were pre-treated with brefeldin A to collapse the Golgi stack. This implies that 
the uptake pathway of the SLT-Ma chimeras is identical to that of native toxin. 
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To confirm the entirety of the influenza Matrix peptide within the SLT-Ma fusion 
proteins, the toxin chimeras were analysed by electrospray ionization (ESI) mass 
spectrometry. The presence of the full influenza Matrix nonamer in both constructs 
was confirmed with molecular masses of 33148.47 +/- 0.31 and 33148.08 +/- 2.83 
Da for SLT N-Ma and C-Ma respectively (predicted mass 33148.47) when the fusion 
proteins were purified in the presence of a protease inhibitor cocktail (Boehringer 
Mannheim). 
8.3 HeLa-A2 cells incubated with SLTN-Ma but not SLTC-Ma are sensitised 
for lysis by Matrix specific CTL. 
Hela-A2 cells treated with 20ng/ml SLTN-Ma (equivalent to 0.6nM) were sensitised 
for lysis by Matrix 58-66 specific CTL (Chapter 5). In contrast, no lysis was 
observed after the addition of SLTC-Ma, even though it was shown by cytotoxicity 
assays to be internalised by HeLa-A2 cells. Presentation of the M58-66 epitope 
contained within the full length Matrix protein and SLTN-Ma was enhanced by 
interferon-y treatment. This is consistent with a IFN-y-dependent upregulation of the 
class-1 processing and presentation pathway. Indeed, expression of the MHC- 
encoded proteasomal subunits, LMP2 and LMP7, was significantly enhanced after 
incubation of HeLa cells with IFN-y as shown by Western blotting using anti-LMP2 
and anti-LMP7 mouse monoclonal antibodies. FACS analysis of IFN-y treated 
HeLA-A2 cells also confirmed that MHC class 1 molecules are generally 
upregulated by IFN-y. 
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An additional effect of IFN-y treatment, which may contribute to the enhancement of 
delivery and presentation of the M58-66 epitope by SLTN-Ma, is that wtSLTN-Ma 
cytotoxicity is increased 3-fold when HeLa-A2 cells are pretreated with interferon-y. 
This is likely to be due to an overall upregulation of trafficking in the cell by IFN-y. . 
8.4 The M58-66 epitope must be internalised to sensitise target cells for lysis. 
To confirm that the M58-66 epitope of SLTN-Ma was generated by intracellular 
proteases rather than serum proteases, the melanoma line Skmel-29, which is 
naturally resistant to SLT was used as target cells. Skmel-29, whilst sensitised for 
lysis when free A2-MAGE-3 peptide 271-279 was applied, were not sensitised for 
lysis by the addition of 20ng/ml SLTN-Ma to cells. In addition, treatment of HeLa- 
A2 cells with BFA successfully blocked the presentation of the M58-66 epitope by 
class-1 molecules at the cell surface. The finding that BFA also blocks the 
cytotoxicity of wild-type SLTN-Ma suggests that the fusions follow the same 
pathway as native SLT, a route via the Golgi to the ER. Since BFA could inhibit 
both the transport of SLTN-Ma to the ER and the association and transport of 
processed peptides with nascent class-I molecules to the cell surface, its exact mode 
of inhibition remains unclear. However as described earlier (section 8.1), it seems 
unlikely that peptide loading of MHC class-1 molecules can occur in endosomes as 
the affinity for class-1 molecules and peptide is low below pH7. 
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8.5 The generation of the M58-66 epitope from SLTN-Ma is independent of 
proteasomal processing. 
The proteasomal inhibitor lactacystin did not block the processing and presentation 
of the M58-66 epitope from SLTN-Ma as has also been shown for the full length 
influenza Matrix protein (V. Cerundolo, personal communication). This suggests 
that non-proteasomal cytosolic proteases may be involved in the generation of the 
M58-66 epitope. Although it is clear that proteasomes play an important role in the 
processing of antigens for presentation by the MHC class-I pathway it has become 
apparent that there are other proteolytic systems that compensate for the loss of 
proteasomal activity, induced by the addition of proteasomal inhibitors such as 
lactacystin (Glas et al., 1998). Alternative processing in the ER has been suggested 
(Elliot et al., 1995, Snyder et al., 1997). Studies with minigenes encoding peptide 
epitope precursors, preceded by the influenza hemagglutinin ER translocation 
sequence, have shown that processing of polypeptides of at least 40 residues can 
occur in the ER of TAP-negative cell-lines. Recently antigen processing in the 
secretory pathway has been investigated with a role for the Golgi-resident protease, 
furin in alternative processing pathways (Gil-Torregrosa et al., 1998), which is of 
interest for SLT fusion proteins which reach the ER via the Golgi. Furin is the 
cellular enzyme responsible for the proteolytic cleavage and separation of the two A- 
chain domains necessary for the full activity of SLT (Garred et al., 1995). 
It is unclear where in the cell (ER or cytosol), the SLT-Ma chimeras are being 
processed. If processing of the SLT-Ma fusions is dependent on cytosolic proteases, 
this may explain why peptide presentation by class-I molecules did not occur when 
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cells were treated with SLTC-Ma. SLTC-Ma has M58-66 located at the C-terminal 
end of the A2 fragment, a region that is unlikely to translocate from the ER to the 
cytosol. This observation is made from studies of cholera toxin, (Majoul et al., 
1996), another AB5 structure bacterial toxin where the Al fragment alone is known 
to translocate to the cytosol after its reduction from the A2 fragment in the ER 
lumen. SLTN-Ma contains the antigenic peptide on the Al fragment which is 
normally the catalytic portion of the toxin that is capable of reaching the cytosol. 
Therefore a fusion with Ma at the N-terminus of SLT would be predicted to reach 
the cytosol for processing if this event were not possible in the ER lumen. 
8.6 Catalytic activity and stability measurements of a novel `double' active-site 
substitution of ricin A-chain. 
The advantage of creating ricin fusion proteins is the potential to deliver peptide to 
all cells, including professional antigen presenting cells, such as dendritic cells. In 
addition, a drawback to using any `carrier' system as a vaccine is that eventually the 
recipient will raise an immune response against the carrier protein itself and the 
vaccine will no longer be effective. It is therefore important to test as many delivery 
vehicles as possible for their ability to deliver exogenous antigen MHC to class-1 
molecules. A long-term protective CTL-vaccine programme may necessitate the use 
of alternate antigen-carriers. 
Ideally, a peptide delivery system should be non-toxic. This can be achieved using 
SLT by fusing peptides to the SLT B-chain and expressing the B-chain chimera 
alone but this is impossible with ricin as the B-chain is unstable when expressed 
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without ricin A-chain. The catalytic mutations E177D and R180H of ricin A-chain 
were combined in an attempt to produce a catalytically inactive mutant ricin. The in 
vitro ribosome depurination activity of E177D R180H was assessed by aniline- 
cleavage assays and the catalytic activity of E177D R180H RTA estimated to be a 
1000-fold down from wild-type RTA (Chapter 7). At 100ng/ml reassociated E177D 
R180H ricin, no activity was seen against HeLa cells compared to an IC50 of 
0.1ng/ml calculated for wild-type ricin. 
However E177D R180H RTA was found to be unstable, lasting only 2-3 weeks at 
4°C before precipitating. This instability was confirmed by testing the thermal 
stability of the mutant RTA and its sensitivity to proteolysis over a range of pH 
values. The addition of a peptide (M58-66 or NP366-374) at the N-terminus of 
E177D R180H RTA further destabilised the protein and altered the binding affinity 
of RTA for CM-Sepharose leading to the conclusion that E177D R180H ricin was 
an unsuitable vehicle for peptide delivery. 
8.7 Construction of R180H ricin chimeras for the delivery of NP 366-374 
epitope to MHC class-1 molecules. 
R180H RTA fusion proteins placing influenza Nucleoprotein 366-374 (NP) peptide 
at the N-terminus of RTA or within the CIaI site of RTA were reassociated with ricin 
B-chain. The generation of the NP366-374 epitope from full length influenza 
Nucleoprotein has been shown to be dependent on proteasomal processing (V. 
Cerundolo, personal communication). Thus the ricin fusion proteins are of interest 
as their processing requirements can be studied using the proteasome inhibitor 
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lactacystin. In addition, the importance of epitope position (at the end or within a 
toxin subunit) can be investigated. 
Murine L cells (H-2Db haplotype) treated with the ricin-NP chimeras (2.5ng/ml) 
were tested for sensitisation to lysis by Nucleoprotein 366-374-specific CTL. 
Infection of L cells with a vaccinia virus encoding influenza Nucleoprotein sensitises 
them for lysis by matched CTL albeit at a low level. However no killing is observed 
with L cells treated with a low concentration of ricin-NP chimeras indicating that in 
this assay and at the toxin concentration tested, ricin is unable to deliver NP into the 
MHC class-1 pathway. Further experiments are necessary to determine whether 
cells are sensitised for lysis by CTL when treated with higher concentrations of ricin- 
NP fusions. Successful SLT or ricin fusions could then be titrated to calculate the 
maximum concentration limit of each toxin and the highest obtainable percentage 
specific cell lysis. 
8.8 Future directions for the exploitation of RIPs in antigen delivery. 
The delivery of a single peptide epitope to MHC class-i molecules is clearly only 
useful as a model system, which was the intent of this research project. An effective 
CD8+ T cell-vaccine should generate a range of antigenic peptides suitable for 
presentation by a number of class-1 haplotypes present in the population. Thus a 
useful vaccine approach would be to deliver a whole antigenic protein into the MHC 
class-i processing pathway. 
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Recently, the B chain of Shiga-toxin (ST) has been used to successfully deliver a 
peptide from the Mage 1 tumour antigen to MHC class-1 molecules (Lee et al.., 
1998). Processing and presentation appeared to involve trafficking of toxin chimeras 
to the ER of target cells. Both subunits of the ST/SLT family have therefore been 
shown to deliver peptide to class-1 molecules. The B fragment of ST/SLT has the 
advantage of being non toxic to cells but is believed not to translocate to the cytosol 
from the ER (unpublished observations from the toxin group laboratory). SLT 
holotoxin with its membrane translocating A chain component may therefore be of 
greater utility when whole antigens are to be delivered if there is a requirement for 
conventional proteasomal degradation. 
SLT holotoxin vaccines may be of additional value; It is interesting to note that a 
theory has been suggested that the immune system only responds to a threat when 
cell damage or death occurs in the host (Matzinger et al., 1998) It is at this point that 
damaged or dying cells send out an additional signal that allows the initiation of an 
immune response. If this is the case then low level cytotoxicity may be beneficial, 
for instance, in certain tumour vaccines. 
As noted above (section 6.8) it is important to test other toxins for their use in 
peptide delivery since the recipient of a vaccine will eventually raise an immune 
response against the carrier protein itself (or may have been vaccinated against the 
vaccine vehicle). Ricin fusion proteins offer the potential to deliver peptide to all 
cells. Professional antigen presenting cells (APCs), such as dendritic cells appear to 
be critical for the initiation of an immune response (Cayeux et al., 1999), providing 
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the necessary non-specific co-stimulatory signal, required to prime antigen-specific 
CTL. The sensitivity of APCs to SLT and ricin should be investigated. 
The antigenic properties of the carrier toxins are also important in vaccine design. 
MHC class-II peptide presentation and induction of CD4+ T helper cell signalling is 
thought to be required for the production of long-lived memory CTLs (Ridge et al., 
1996). Class-II-specific epitopes may be generated from the processing of the 
carrier toxin. Alternatively class-II specific peptides may be encoded within the 
toxin. These issues may be better addressed by investigating the delivery of peptides 
by SLT and ricin using an animal model. This is the long term goal of future 
research in this area. 
8.9 The future of vaccines 
Although live or attenuated virus vaccines such as polio, measles, mumps and 
rubella, have been very successful. For certain pathogens, such as HIV, there have 
been safety concerns about the reversion of attenuated vaccine strains to virulent 
phenotypes. In addition there have been concerns over the potential side-effects of 
certain vaccines, for example the combination measles/mumps/rubella (MMR) 
vaccine that may out-way the benefits of the vaccine. This has led to the research for 
safer vaccine vehicles, some of which have reached the stage of clinical trials. 
DNA vaccines in clinical trials include vaccines against hepatitis B, genital herpes 
and an influenza virus vaccine. The advantages of DNA vectors in vaccine design is 
that they encode multiple epitopes for many BLA allelles. This is also true for 
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mRNA-based vaccines. A disadvantage of plasmid DNA encoded vaccines is that 
chromosomal intergration of foreign DNA may occur. If after vaccination, DNA is 
taken up by fetal or germ-line cells, immunological tolerance may be induced in the 
progeny. Tolerant progeny would be more susceptible to infection or may become 
carriers which would affect the whole population. RNA-vaccines are a safer option 
but RNA itself is extremely labile, in contrast to DNA vaccines that are stable and do 
not require cold-storage. In addition, DNA-vaccines that encode antigens under the 
control of a strong eukaryotic promoter (usually cytomegalovirus enhancer- 
promoter) have generated a sustained humoral and cell-mediated response. Thus the 
benefits of DNA-based vaccines may outweigh the potential risks of chromosomal 
integration. 
In animal models (mice and chimpanzees), protection against Ebola virus (Xu et al., 
1998), malaria (Schneider et al., 1998) and HIV (Hanke et al., 1999) have been 
reported by use of DNA-based vaccination that correlate with high levels of 
activated CTLs in the spleens of animals. T cell induction has been enhanced by the 
subsequent boosting of DNA vaccines with a modified vaccinia virus (MVA) 
(Hanke et al., 1999). Used together, the level of CTL induction is far greater than if 
either of the vectors were used as both the priming and boosting vaccine. If 
combinations of vaccine vectors raises the protective immune response against 
pathogens then it is important to have a number of vaccine vehicles capable of 
eliciting a MHC class I restricted CTL response. Disarmed toxins may therefore in 
the future be used in combination with other vaccines. Another important factor is 
that if boosting is required to maintain protective cellular immunity then eventually 
antibodies against the vaccine vector will be raised upon subsequent immunization. 
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One of the drawbacks to viral or bacterial based vaccines is that neutralizing 
antibodies already exist for example by previous exposure to crossreacting viruses (a 
problem with adenovirus vectors) or previous immunization (vaccinia) (Pardoll et 
al., 1998). Therefore the continued study of alternative T-cell vaccine vehicles is an 
important aspect in the progress towards safe and protective immunization regimes 
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Appendix 1 
DNA and amino acid sequences of the SLT operon from E. coli phage H19B 
(Calderwood et al., 1987). Shine-Dalgarno sequences are underlined and indicated 
by SD. Proposed signal peptide cleavage sites are indicated by vertical arrows. 
Numbers refer to amino acid residues in each polypeptide. Negative numbers 
designate residues in the signal peptide, and positive numbers designate residues in 
the mature protein. 
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GCTCAAGGAG TATTGTGTAA"T ATG AAA ATA ATT ATT TTT AGA GTG CTA ACT TTT -12 
SD Met Lys Ile Ile Ile Phe Arg Val Leu Thr Phe 
TTC TTT GTT ATC TTT TCA GTT AAT GTG GTG GCG AAG GAA TTT ACC TTA GAC 6 
Phe Phe Val Ile Phe Ser Val Asn Val Val AlatLys Glu Phe Thr Leu Asp 
TTC TCG ACT GCA AAG ACG TAT GTA GAT TCG CTG AAT GTC ATT CGC TCT GCA 23 
Phe Ser Thr Ala Lys Thr Tyr Val Asp Ser Leu Asn Val Ile Arg Ser Ala 
ATA GGT ACT CCA TTA GAG ACT ATT TCA TCA GGA GGT ACG TCT TTA CTG ATG 40 
Ile Gly Thr Pro Leu Gln Thr Ile Ser Ser Gly Gly Thr Ser Leu Leu Met 
ATT GAT AGT GGC TCA GGG GAT AAT TTO TTT GCA GTT GAT GTC AGA GGG ATA 57 
Ile Asp Ser Gly Ser Gly Asp Asn Leu Phe Ala Val Asp Val Arg Gly Ile 
GAT CCA GAG GAA GGG CGG TTT AAT AAT CTA CGG CTT ATT GTT GAA CGA AAT 74 
Asp Pro Glu Glu Gly Arg Phe Asn Asn Leu Arg Leu Ile Val Glu Arg Asn 
AAT TTA TAT GTG ACA GGA TTT GTT AAC AGG ACA AAT AAT GTT TTT TAT CGC 91 
Asn Leu Tyr Val Thr Gly Phe Val Asn Arg Thr Asn Asn Val Phe Tyr Arg 
TTT GCT GAT TTT TCA CAT GTT ACC TTT CCA GGT ACA ACA GCG GTT ACA TTG 108 
Phe Ala Asp Phe Ser His Val Thr Phe Pro gly Thr Thr Ala Val Thr Leu 
TCT GGT GAC AGT AGC TAT ACC ACG TTA CAG CGT CTT GCA GGG ATC AGT CGT 125 
Ser Gly Asp Ser Ser Tyr Thr Thr Leu Gin Arg Val Ala Gly Ile Ser Arg 
ACG GGG ATG CAG ATA AAT CAG CAT TCG TTG ACT ACT TCT TAT CTG GAT TTA 142 
Thr Gly Met Gln Ile Asn Arg His Ser Leu Thr Thr Ser Tyr Leu Asp Leu 
ATO TCC CAT AGT GGA ACC TCA CTG ACG CAG TCT GTG GCA AGA GCG ATG TTA 159 
Met Ser His Ser Gly Thr Ser Leu Thr Gln Ser Val Ala Arg Ala Met Leu 
CGG TTT GTT ACT GTG ACA GCT GAA GCT TTA CGT TTT CGG CAA ATA CAG AGG 176 
Arg Phe Val Thr Val Thr Ala Glu Ala Leu Arg Phe Arg Gln Ile Gln Arg 
GGA TTT CGT ACA ACA CTG GAT GAT CTC AGT GGG CGT TCT TAT GTA ATG ACT 193 
Gly Phe Arg Thr Thr Leu Asp Asp Leu Ser Gly Arg Ser Tyr Val Met Thr 
GCT GAA GAT GTT GAT CTT ACA TTG AAC TGG GGA ACG TTG AGT AGC GTC CTG 210 
Ala Glu Asp Val Asp Leu Thr Leu Asn Trp Gly Arg Leu Ser Ser Val Leu 
CCT GAC TAT CAT GGA CAA GAC TCT GTT CGT GTA GGA AGA ATT TCT TTT GGA 227 
Pro Asp Tyr His Gly Gln Asp Ser Val Arg Val Gly Arg Ile Ser Phe Gly 
AGC ATT AAT GCA ATT CTG GGA AGC GTG GCA TTA ATA CTG AAT TGT CAT CAT 244 
Ser Ile Asn Ala Ile Leu Gly Ser Val Ala Leu I1e'Leu Asn Cys His His 
CAT GCA TCC CGA GTT GCC AGA ATG GCA TCT GAT GAG TTT CCT TCT ATO TGT 261 
His Ala Ser Arg Val Ala Arg Met Ala Ser Asp Glu Phe Pro Ser Met Cys 
CCG GCA GAT GGA AGA GTC CGT GGG ATT ACG CAC AAT AAA ATA TGT TGG GAT 278 
Pro Ala Asp Gly Arg Val Arg Gly Ile Thr His Asn Lys Ile Leu Trp Asp 
TCA TCC ACT CTG GGG GCA ATT CTG ATG CGC AGA ACT ATT AGC AGT TGAGGGGG 
Ser Ser Thr Leu Gly Ala Ile leu Met Arg Arg Thr Ile Ser Ser SD 
TA AA ATG AAA AAA ACA TTA TTA ATA GCT GCA TCG CTT TCA TTT TTT TCA -6 
Met Lys Lys Thr Leu Leu Ile Ala Ala Ser Leu Ser Phe Phe Ser 
GCA AGT GCG CTG GCG ACG CCT GAT TGT GTA ACT GGA AAG GTG GAG TAT ACA 11 
Ala Ser Ala Leu Ala1Thr Pro Asp Cys Val Thr Gly Lys Val Glu Tyr Thr 
AAA TAT AAT GAT GACIGAT ACC TTT ACA GTT AAA GTG GGT GAT AAA GAA TTA 28 
Lys Tyr Asn Asp Asp Asp Thr Phe Thr Val Lys Val Gly Asp Lys Glu Leu 
TTT ACC AAC AGA TGG AAT CTT CAG TCT CTT CTT CTC AGT GCG CAA ATT ACG 45 
Phe Thr Asn Arg Trp Asn Leu Gln Ser Leu leu Leu Ser Ala Gln Ile Thr 
GGG ATG ACT GTA ACC ATT AAA ACT AAT GCC TGT CAT AAT GGA GGG GGA TTC 62 
Gly Met Thr Val Thr Ile Lys Thr Asn Ala Cys His Asn Gly Gly Gly Phe 
AGC GAA GTT ATT TTT CGT TGA 
Ser Glu Val Ile Phe Arg STOP 
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Appendix 2 
DNA and amino acid sequences of mature ricin from Ricinus communis (Roberts et 
al., 1985). Numbers refer to amino acid residues in each polypeptide. 
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ATA TTC CCC AAA CAA TAC CCA ATT ATA AAC TTT ACC ACA GCG GGT GCC ACT 17 
Ile Phe Pro Lys Gln Tyr Pro Ile Ile Asn Phe Thr Thr Ala Gly Ala Thr 
GTG CAA AGC TAC ACA AAC TTT ATC AGA GCT GTT CGC GGT CGT TTA ACA ACT 34 
Val Gln Ser Tyr Thr Asn Phe Ile Arg Ala Val Arg Gly Arg Leu Thr Thr 
GGA GCT GAT GTG AGA CAT GAA ATA CCA GTG TTG CCA ACC AGA GTT GGT TTG 51 
Gly Ala Asp Val Arg His Glu Ile Pro Val Leu Pro Asn Arg Val Gly Leu 
CCT ATA AAC CAA CGG TTT ATT TTA GTT GAA CTC TCA AAT CAT GCA GAG CTT 68 
Pro Ile Asn Gln Arg Phe Ile Leu Val Glu Leu Ser Asn His Ala Glu Leu 
TCT GTT ACA TTA GCC CTG GAT GTC ACC AAT GCA TAT GTG GTC GGC TAC CGT 85 
Ser Val Thr Leu Ala Leu Asp Val Thr Asn Ala Tyr Val Val Gly Tyr Arg 
GCT GGA AAT AGC GCA TAT TTC TTT CAT CCT GAC AAT CAG GAA GAT GCA GAA 102 
Ala Gly Asn Ser Ala Tyr Phe Phe His Pro Asp Asn Gln Glu Asp Ala Glu 
GCA ATC ACT CAT CTT TTC ACT GAT GTT CAA AAT CGA TAT ACA TTC GCC TTT 119 
Ala Ile Thr His Leu Phe Thr Asp Val Gln Asn Arg Tyr Thr Phe Ala Phe 
GGT GGT AAT TAT GAT AGA CTT GAA CAA CTT GCT GGT AAT CTG AGA GAA AAT 136 
Gly Gly Asn Tyr Asp Arg Leu Glu Gln Leu Ala Gly Asn Leu Arg Glu Asn 
ATC GAG TTG GGA AAT GGT CCA CTA GAG GAG GCT ATC TCA GCG CTT TAT TAT 153 
Ile Glu Leu Gly Asn Gly Pro Leu Glu Glu Ala Ile Ser Ala Leu Tyr Tyr 
TAC AGT ACT GGT GGC ACT CAG CTT CCA ACT CTG GCT CGT TCC TTT ATA ATT 170 
Tyr Ser Thr Gly Gly Thr Gln Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile 
'TGC ATC CAA ATG ATT TCA GAA GCA GCA AGA TTC CAA TAT ATT GAG GGA GAA 187 
Cys Ile Gln Met Ile Ser glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly Glu 
ATO CGC ACG AGA ATT AGG TAC AAC CGG AGA TCT GCA CCA GAT CCT AGC GTA 204 
Met Arg Thr Arg Ile Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser Val 
ATT ACA CTT GAG AAT AGT TGG GGG AGA CTT TCC ACT GCA ATT CAA GAG TCT 221 
Ile Thr Leu Glu Asn Ser Trp Gly Arg Leu Ser Thr Ala Ile Gln Glu Ser 
AAC CAA GGA GCC TTT GCT AGT CCA ATT CAA CTG CAA AGA CGT AAT GGT TCC 238 
Asn Gln Gly Ala Phe Ala Ser Pro Ile Gln Leu gln Arg Arg Asn Gly Ser 
AAA TTC AGT GTG TAC GAT GTG AGT ATA TTA ATC CCT ATC ATA GCT CTC ATO 255 
Lys Phe Ser Val Tyr Asp Val Ser Ile Leu Ile Pro Ile Ile Ala Leu Met 
GTG TAT AGA TGC GCA CCT CCA CCA TCG TCA CAG TTT 
Val Tyr Arg Cys Ala Pro Pro Pro Ser Ser Gln Phe 
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